Find information on thousands of medical conditions and prescription drugs.

Brevicon

Oral contraceptives come in a variety of formulations. The main division is between combined oral contraceptive pills, containing both estrogen and progesterone, and progesterone only pills (mini-pills). Combined oral contraceptive pills also come in varying types, including varying doses of estrogen, and whether the dose of estrogen or progesterone changes from week to week. more...

Home
Diseases
Medicines
A
B
Baciim
Bacitracin
Baclofen
Bactrim
Bactroban
Barbexaclone
Barbital
Baros
Basiliximab
Baycol
Beclamide
Beclometasone
Beclovent
Beconase
Beldin
Benadryl
Benazepril
Bendroflumethiazide
Benserazide
Bentiromide
Benylin
Benzaclin
Benzalkonium chloride
Benzocaine
Benzonatate
Betacarotene
Betadine
Betahistine
Betamethasone
Betaxolol
Bextra
Biaxin
Bibrocathol
Bicalutamide
Bicillin
Biclotymol
Biotin
Bisoprolol
Bleomycin
Blocadren
Boldenone
Boniva
Bontril
Bosentan
Bravelle
Brethaire
Brevibloc
Brevicon
Bricanyl
Bromazepam
Bromelain
Bromhexine
Bromocriptine
Brompheniramine
Bronkodyl
Bronopol
BSS
Bucet
Budesonide
Bumetanide
Bupivacaine
Buprenex
Buprenorphine
Buserelin
Buspar
Buspirone
Busulfan
Butalbital
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Combined oral contraceptive pills

All contain the estrogen ethinyl estradiol, although in varying amounts, and one of a number of different progesterones. They are taken for 21 days with then a 7 day gap during which a withdrawal bleed (often, but incorrectly, referred to as a menstrual period) occurs. These differ in the amount of estrogen given, and whether they are monophasic (only one dose of estrogen and progesterone during the 21 days) or multiphasic (varying doses).

Monophasic

These are given as 21 tablets of estrogen and progesterone, followed by 7 tablets of placebo. Different formulations contain different amounts of estrogen and progesterone:

  • 20 mcg estrogen
    • 0.1 mg levonorgestrel (Alesse®, Levline®)
    • 1 mg norethindrone acetate (Loestrin 1/20®Fe)
  • 30 mcg estrogen
    • 0.15 mg levonorgestrel (Levlen®, Levora®, Nordette®)
    • 0.3 mg norgestrel (Lo-Ovral®)
    • 0.15 mg desogestrel (Desogen®, Organon; Ortho-Cept®, Ortho-McNeil)
    • 1.5 mg norethindrone acetate (Loestrin® 1.5/30)
    • 3.0 mg drospirenone (Yasmin®)
  • 35 mcg estrogen
    • 0.25 mg norgestimate (Ortho-Cyclen®)
    • 0.4 mg norethindrone (Ovcon-35®, Warner Chilcott)
    • 0.5 mg norethindrone (Modicon®, Brevicon®)
    • 1 mg norethindrone (Ortho-Novum 1/35®, Necon®, Norethin®, Norinyl 1/35®)
    • 1 mg ethynodiol diacetate (Demulen 1/35®, Zovia 1/35E®)
  • 50 mcg estrogen
    • 0.4 mg norethindrone (Ovcon-50®, Warner Chilcott))
    • 1 mg norethindrone (Necon 1/50®, Norinyl 1/50®, Ortho-Novum 1/50®, Ovcon-50®)
    • 0.5 mg norgestrel (Ovral®)
    • 1 mg ethynodiol diacetate (Demulen 1/50®, Zovia 1/50E®)

Multiphasic

  • Desogestrel 0.15 mg and ethinyl estradiol 0.02 mg x 14 tablets, followed by ethynil estradiol 0.01 mg x 2 tablets, followed by 5 tablets of placebo (Kariva®, Barr Laboratories; Mircette®, Organon)
  • Desogestrel 0.1 mg ethynil estradiol 0.025 mg x 7 tablets, followed by desogestrel 0.125 mg and ethynil estradiol 0.025 mg x 7 tablets, followed by desogestrel 0.15 mg and ethynil estradiol 0.025 mg x 7 tablets, followed by 7 tablets of ferric oxide (Cyclessa®, Organon; Velivet®, Barr Laboratories)
  • Norethindrone 0.5 mg and ethinyl estradiol 0.035 mg x 7 tablets, followed by 0.75 mg of norethindrone and 0.035 mg of ethinyl estradiol x 7 tablets, followed by 1 mg of norethindrone and 0.035 of ethinyl estradiol, followed by 7 tablets of placebo (Ortho-Novum 7/7/7®)
  • Norethindrone 0.5 mg and 0.035 mg of ethinyl estradiol x 10 tablets, followed by 1 mg norethindrone and 0.035 ethinyl estradiol x 11 tablets, followed by 7 tablets of placebo (Ortho-Novum 10/11®)

Read more at Wikipedia.org


[List your site here Free!]


Bibliography - bibliography
From Population Reports, 11/1/88 by Chris Wharton

Bibliography An asterisk (*) denotes an item that was particularly useful in the preparation of this issue of Population Reports.

1. ANONYMOUS. Another look at the pill and breast cancer. Lancet 2(8462):985-987. Nov. 2,1985.

2. ANONYMOUS. Children of pill users who breastfeed show no growth deficiencies. International Family Planning Perspectives 8(1): 30-31. Mar. 1982.

3. ANONYMOUS. Dominican Republic 1986: results from the Demographic and Health Survey. Studies in Family Planning 19(2): 122-126. Mar.-Apr. 1988.

4. ANONYMOUS. Funding cuts halt UK pill safety study. IPPF Open File, Aug.-Sep. 15, 1988. p. 19.

5. ANONYMOUS. General discussion [of factors affecting acceptance and compliance in use of oral contraceptional]. Singapore Journal of Obstetrics and Gynaecology 15(1, Supp.): 119-123. Mar. 1984.

6. ANONYMOUS. Hormone receptors positive prognostic indicators in breast cancer. Ob. Gyn. News 22(12): 18. Jun. 15-30, 1987.

7. ANONYMOUS. Liberia 1986: results from the Demographic and Health Survey. Studies in Family Planning 19(4)d 250-254. Jul.-Aug. 1988.

8. ANONYMOUS. Liver cancer and long-term use of oral contraceptives. British Journal of Family Planning 12(3): 103-104. Oct. 1986.

9. ANONYMOUS. Low-dose oral contraceptives and cardiovascular disease. NIHI Guide for Grants and Contracts 18(6): 3. Feb. 54, 1989.

10. anonymous. Oral contraceptives and breast cancer. Lancet 2(8395): 145. Jul. 21, 1984.

11. ANONYMOUS. Oral contraceptives and breast cancer. Lancet 2(8508): 665-666. Sep. 20, 1986.

12. ANONYMOUS. Oral contraceptives and neoplasia. Lancet 2(8356): 947-948. Oct. 22, 1983.

13. ANONYMOUS. Subclinical penile HPV may be related to partner's cervical ca. Ob.Gyn. News 23(20): 25. Oct. 15-31, 1988.

14. ABDEL-AZIZ, A., ANDERSON, J.E., MORRIS, L., WINGO, P., and SHRYDEH, B. Family Planning in Jordan: 1983 survey data. Studies in Family Planning 17(4): 199-206. Jul.-Aug. 1986.

15. ADAM, S.A., SHEAVES, J.K., WRIGHT, N.H., MOSSER, G., HARRIS, R.W., AND VESSEY, M.P. A case-control study of the possible association between oral contraceptives and malignant melanoma. british Journal of Cancer 44(1):45-50. Jul. 1981.

16. ALAN BUTTMACHER INSTITUTE. FDA panel examines link between breast cancer, pill, says more research needed. Washington Memo, W-3:3-4. Jan. 18, 1989.

17. ALBUQUERQUE, L.A., ALBUQUERQUE, E.G., WASZAK, C.S., ROWAN, A.M., and BARTHLOW, D. A comparative clinical trial of Norinyl 1/35 versus Brevicon in rio Clara, Brazil. Contraception 38(5): 525-539. Nov. 1988.

18. ALLEN, H.H. Clinical assessment of a low-dose oestrogen, low-dose progestogen combined oral contraceptive. Current Medical Research and Opinion 2(2): 101-108. 1974.

19. ANDERSCH, B. and HAHN, L. Premenstrual complaints: 2. Influence of oral contraceptives. Acta Obstetricia et Gynecologica Scandinavica 60(6): 579-583. 1981.

20. ANNEGERS, J.R., STROM, H., DECKER, D.G., DOCKERTY, M.B., and O'FALLON, W.M. Ovarian cancer: incidence and case control study. Cancer 43(2): 723-729. Feb. 1979.

21. APELO, R. and VELOSO, I. Clinical experience with ethinyl estradiol and d-norgestrel as an oral contraceptive. Fertility and Sterility 26(30): 283-288. Mar. 1975.

22. APELO, R.A. and SUPLIDO, A. Clinical assessment of a new triphasic oral contraceptive. Clinical Therapeutic 8(1):61-70. 1985.

23. ARAL, S.O., MOSHER, W.D., and CATES, W., Jr. Contraceptive use, pelvic inflammatory disease, and fertility problems among American women: 1982. American College of Obstetrics and Gynecology 157(1): 59-64. Jul. 1987.

24. ARNT, I.C., FERRARI, A., SARTORETTO, J.N., and WOUTERSZ, T.B. Low-dose combination oral contraceptives: a controlled clinical study of three different norgestrel-ethinyl estradiol ratios. Fertility and Sterility 28(5): 549-553. May 1977.

25. ARRUDA, J.M., RUTENBERG, N., MORRIS. L., and FERRAZ, E.A. Pesquisa Nacional sobre Saude Matemo-Infantil e Planejamento Familiar Brasil--1986. [Brazil National Survey of Matemal and Child Health and Family Planning--1986.] [POR] Rio de Janeiro and Columbia, Maryland, Sociedade Civil Bem-Estar Familiar no Brazil (BEMFAM). and Institute for Resource Development/Westinghouse, Dec. 1987. 234 p.

26. ARSHAT, H. A comparative study of Loestrin versus Nordette in Kelantan, West Malaysia. Malaysian Journal of Reproductive Health 2(1)d 25-31. 1984.

27. BACIEWICZ, A.M. Oral contraceptive durg interactions. Therapeutic Drug Monitoring 7(1): 26-35. Mar. 1985.

28. BADRAOUI, M.H. and ASKALANI, H. Effect of low-dose combined OCs on lactation patterns. Contraceptive Delivery Systems 4(4): 327-329. Sep. 1983.

29. BADRAOUI, M.H.H., HEFNAWI, F., and ASKALANI, H. The value of breast feeding in developing countries (with reference to Islamic population). Population Sciences 4: 17-31. 1983.

30. BALAKRISHNAN, T.R., KROTKI, K., and LAPIRRE-ADAMCYK, E. Contraceptive use in Canada, 1984. Family Planning Perspective 17(5): 209-215. Sep.-Oct. 1985.

31. BARBADOS FAMILY PLANNING ASSOCIATION (BFPA). Contraceptive Prevalence Surveys: a comparative study of contraceptive prevalence in Antigua, Dominica, St. Lucia and St. Vincent, Bridgetown, Barbados and Columbia, BFPA and Westinghouse Health Systems, Sep. 1983. 83p.

32. BARNETT, M.L. Inhibition of oral contraceptive effectiveness by concurrent antibiotic administration: a review. Journal of Periodontology 56(1)d 18-20. Jan. 1985.

33. BARTON, S.E., MADDOX, P.H., JENKINS. D., EDWARDS, R., CUZICK, J., and SINGER, A. Effect of cigarett smoking on cervical epithelial immunity: a mechanism for neoplastic change? Lancet 2(8612): 652-654. Sep. 17, 1988.

34. BASNAYAKE, S., DE SILVA, S.V., MILLER, P.C., and ROGERS, S. A comparison of Norinyl and Brevicon in three sites in Sri Lanka. Contraception 27(5): 453-464. May 1983.

* 35. BELLAGIO CONSENSUS CONFERENCE ON LACTATIONAL INFERTILITY. Consensus statement: breastfeeding as a family planning method. Lancet 2(8621): 1204-1205. Nov. 19, 1988.

36. BERAL, V., HANNAFORD, P., and KAY, C. Oral contraceptive use and malignancies of the genital tract: results from the Royal College of General Practitioners' Oral Contraception Study. Lancet 2(8624): 1313-1335. Dec. 10, 1988.

37. BERENT, J. Family planning in Europe and USA in the 1970s. Voorburg, Netherlands, International Statistical Institute, Oct. 1982. (World Fertility Survey Studies No. 20) 33 p.

38. BERGER, G.S., EDELMAN, D.A., and TALWAR, P.P. The probability of side effects with Ovral, Norinyl 1/50 and Norlestrin 1. Contraception 20(5): 447-453. Nov. 1979.

39. BERGSTEIN, N.A.M. Clinical efficay, acceptability and metabolic effects of new low dose combined oral contraceptives. Acta Obstetricia et Gynecologica Scandinavica (Supp. 54): 51-59. 1976.

40. BERGSTEIN, N.A.M. Investigation of a new low-dose oral contraceptive: 30 micrograms ethinyl estradiol and 150 micrograms levonorgestrel (d-Norgestre6). Clinical Therapeutics 1(1)d 26-32. 1977.

41. BERKOWITZ, G., KELSEY, J., HOLFORD, T., and LIVOLSI, V. Exogenous hormone use and fibrocystic breast disease among pre and postmenopausal women. Presented at the 16th Annual Meeting of the Society for Epidemiological Research, Winnipeg, Canada, Jun. 15-17, 1983. 6 p.

42. BETANCOURT, J.D., SANDOVAL, J.C., SANCHEZ, F., VALLESTEROS DE CANO, P.V., LUZ BANTISTA, M. DELA, and JIMENEZ, F. Influence of Exluton (progestogen-only OC) and the Multiload Cu 250 IUD on lactation. Contraceptive Delivery System 5(2): 91-95. Apr. 1984.

43. BHATIA, S., BECKER, S., and KIM, Y.J. The effect of oral contraceptive acceptance on fertility in the postpartum period. International Journal of Gynaecology, and Obstetrics 25(Suppl.): 1-11. 1987.

44. BIGGAR, R.J. The AIDS problem in Africa. Lancet 1(8472): 79-83. Jan. 11, 1986.

45. BLUMENSTEIN, B.A., DOUGLAS, M.B., and HALL, W.D. Blood pressure changes and oral contraceptive use: a study of 2676 black women in the southeastern United States. American Journal of Epidemiology 112(4): 539-552. Oct. 1980.

46. BOOHENE, E. and DOW, T.E., Jr. Contraceptive prevalence and family planning program in Zimbabwe. International Family Planning Perspective 13(1): 1-7. Mar. 1987.

47. BOTSWANA. MINISTRY OF FINANCE AND DEVELOPMENT PLANNING (MFDP). CENTRAL STATISTICS OFFICE, and MINISTRY OF HEALTH (MOH). FAMILY HEALTH DIVISION. and DEMOGRAPHIC AND HEALTH SURVEYS (DHS). INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE. Botswana Family Health Survey 2: 1988: preliminary report. [Gaborone], Botswana and Columbia, Maryland, MFDP and MOH and DHS, Jan. 1989. 17 p.

* 48. BOUNDS, W., VESSEY, M., and WIGGINS, P. A randomized double-blind trial of two low dose combined oral contraceptives. British Journal of Obstetrics and Gynaecology 86(4): 325-329. Apr. 1979.

49. BRADLEY, D.D., WINGERD, J., PETITTI, D.B., KRAUSS, R.M., and RAMCHARAN, S. Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. New England Journal of Medicine 299(1): 17-20. Jul. 6, 1978.

50. BRAMLEY, M. and KINGHORN, G. Do oral contraceptives inhibit Trichomonas vaginalis? Sexually Transmitted Diseases 6(4): 261-263. Oct.-Dec. 1979.

51. BRAT, T. Clinical trial with a new low oestrogen combined oral contraceptive. Current Medical Research and Opinion 2(8): 465-470. 1974.

52. BREAST CANCER TRIALS COMMITTEE. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 2(8552): 171-175. Jul. 25, 1987.

53. BRINTON, L.A., HUGGINS, G.R., LEHMAN, H.F., MALLIN, K., SAVITZ, D.A., TRAPIDO, E., ROSENTHAL, J., and HOOVER, R. Long-term use of oral contraceptives and risk of invasive cervical cancer. International Journal of Cancer 38(3)d 339-344. Sep. 15, 1985.

54. BRINTON, L.A., TASHIMA, K.T., LEHMAN, H.F., LEVINE, R.S., MALLIN, K., SAVITZ, D.A., STOLLEY, P.D., and FRAUMENI, J.F., Jr. Epidemiology of cervical cancer by cell type. Cancer Research 47(6): 1706-1711. Mar. 15, 1987.

55. BRINTON, L.A., VESSEY, M.P., FLAVEL, R., and YEATES, D. Rish factors for benign breast disease. American Journal of Epidemiology 113(3): 203-214. Mar. 1981.

56. BROOKS, P.G. Pill formulations and their effect on lipid and carbohydrate metabolism. Journal of Reproductive Medicine 29(7, Supp.): 539-546. Jul. 1984.

57. BROOKS, P.G. The relationship of estrogen and progesterone to breast disease. Journal of Reproductive Medicine 29(7, Supp.): 530-538. Jul. 1984.

58. BURKMAN, R.T., ROBINSON, J.C., KRUSZON-MORAN, D., KIMBALL, A.W., KWITEROVICH, P., and BURFORD, R.G. Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. Obstetrics and Gynecology 71(1): 33-38. Jan. 1988.

59. BURNAKIS, T.G. and HILDEBRANDT, N.B. Pelvic inflammatory disease: a review with emphasis on antimicrobial therapy. Reviews of Infectious Diseases 8(1): 86-116. Jan.-Feb. 1986.

60. BYE, P.G.T. and ELSTEIN, M. Clinical assessment of a lo-oestrogen combined oral contraceptive. British Medical Journal 2(5863): 389-392. May 19, 1973.

61. BYERS, T., GRAHAM, S., RZEPKA, T., and MARSHALL, J. Lactation and breast cancer. American Journal of Epidemiology 121(5): 664-674. May 1985.

62. CAILLOUETTE, J.C. Ovarian cysts and oral contraceptives. [Letter] American Journal of Obstetrics and Gynecology 160(2): 523-524. Feb. 1989.

63. CAILLOUETTE, J.C. and KOEHLER, A.L. Phasic contraceptive pills and functional ovarian cysts. American Journal of Obstetrics and Gynecology 156(6): 1538-1542. Jun. 1987.

64. CAIRNS, V., KEIL, U., DOERING, A., KOENIG, W., STIEBER, J., and KLEINBAUM, D.G. Oral contraceptive use and blood pressure in a German metropolitan population. International Journal of Epidemiology 14(3): 389-395. Sep. 1985.

65. CAMERON, D.W., PLUMMER, F., NDINYA-ACHOLA, J.O., NGUGI, and RONALD, A.R. The use of condoms by the clients of prostitutes reduce the prevalence of genital ulcer disease (GUD). [Abstract] Presented a the 4th International Conference on AIDS, Stockholm, Sweden, Jun. 12-16, 1988.

66. CAMPODONICO G., I., GUERRERO, B., and LANDA I., L. Effect of a low-dose oral contraceptive (150 [mu] g lenonorgestrel and 30 [mu] g ethinylestradiol) on laction. Clinical Therapeutics 1(6): 454-459. 1978.

67. CANCER AND STEROID HORMONE STUDY GROUP. Oral-contraceptive use and the risk of breast cancer. New England Journal of Medicine 315(7): 405-411, Aug. 14, 1986.

* 68. CANCER AND STEROID HORMONE STUDY OF THE CENTERS FOR DISEASE CONTROL AND THE NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT. The reduction in risk of ovarian cancer associated with oral-contraceptive use. New England Journal of Medicines 316(11): 650-655. Mar. 12, 1987.

* 69. CANCER AND STEROID HORMONE STUDY. Combination oral contraceptive use and the risk of endometrial cancer. Journal of the American Medical Association 257(6): 796-800. Feb. 13, 1987.

70. CARAEL, M., VAN DE PERRE, P.H., LEPAGE, P.H., ALLEN, S., NSENGUMUREMYI, F., VAN GOETHEM, C., NTAHORUTABA, M., NZARAMBA, D., and CLUMECK, N. Human immunodeficiency virus transmission among heterosexual couples in Central Africa. AIDS 2(3): 201-205. 1988.

71. CASAGRANDE, J.T., LOUIE, E.W., PIKE, M.C., ROY, S., ROSS, R.K., and HENDERSON, B.E. "Incessant ovulation" and ovarian cancer. Lancet 2(8135): 170-174. Jul. 28, 1979.

72. CELENTANO, D.D. Oral contraceptives and cervical cancer. Journal of the American Medical Association 259(18): 2696. May 13, 1988.

73. CELENTANO, D.D., KLASSEN, A.C., WEISMANN, C.S., and ROSENSHEIN, N.B. The role of contraceptive use in cervical cancer: the Maryland cervical cancer-control study. American Journal of Epidemiology 126(4): 592-604. Oct. 1987.

74. CHAMRATRITHIRONG, A., KAMNUANSILPA, P., and KNODEL, J. Contraceptive practive and fertility in Thailand: results of the third Contraceptive Prevalence Survey. Studies in Family Planning 17(6, Pt. 1): 278-287. Nov.-DEc. 1986.

75. CHAN, W.Y. Prostaglandins and nonsteroidal antiinflammatory drugs in dysmenorrhea. Annual Review of Pharmacology and Toxicology 23: 131-149. 1983.

76. CHANG, M.C. Reminiscences on early pill development. Network 7(4): 6. Summer 1986.

77. CHAO, S. The effect of lactation in ovulation and fertility. Clinics in Perinatology 14(1): 39-50. Mar. 1987.

78. CHATWAL, T. (United Nations Population Fund) [UNFPA OC supplies, 1985-1987] Personal communication, Oct. 10, 1988.

79. CHAYOVAN, N., KAMNUANSILPA, P., and KNODEL, J. Thailand Demographic and Health Survey 1987. Bangkok and Columbia, Maryland, Institute of Population Studies. Chulalongkorn University. and Institute for Resource Development/Westinghouse, May 1988. 217 p.

80. CHIEH-JOHNSON8 D., CROSS, A.R., WAY, A.A.A, and SULLIVAN, J.M. Liberia demographic and health survey 1986. Monrovia, Liberia, and Columbia, Maryland, Republic of Liberia, Bureau of Statistics. and Institute for Resource Development/Westinghouse, Feb. 1988. 117 p.

81. CHILVERS, C., MANT, D., and PIKE, M.C. Cervical adenocarcinoma and oral contraceptives. British Medical Journal 295(6611): 1446-1447. Dec. 5, 1987.

82. CHILVERS, C., MCPHERSON, K., PETO, J., PIKE, M.C., and VESSEY, M.P. Oral contraceptive use and breast cancer risk in young women. Lancet 1(8645): 973-982. May 6, 1989.

83. CHINA POPULATION INFORMATION CENTRE (CPIC). Analysis on China's National One-per-thousand-population Fertility Sampling Survey. Beijing, China, CPIC, 1984. 182 p.

84. CHINA, GENERAL OFFICE OF THE STATE FAMILY PLANNING COMMISSION. Statistics on population and family planning of China: 1986, 1987. 8 p. (Unpublished)

85. CHOUDHURY, A.Y., LAING, J.E., KHAN, A,R., and CLARK, S. Use-effectiveness of oral pills and condoms. Dhaka, Bangladesh, Program for the Introduction and Adaptation of Contraceptive Technology, Nov. 1986. 158 p.

86. CHOWDHURY, V., JOSHI, U.M., GOPALKRISHNA, K., BETRABET, S., MEHTA, S., and SAXENA, B.N. Escape ovulation in women due to the missing of low dose combination oral contraceptive pills. Contraception 22(3): 241-247. Sep. 1980.

87. CLARKE, E.A., HATCHER, J., MCKEOWN-EYSSEN, G.E., and LICKRISH, G.M. Cervical dysplasia: association with sexual behavior, smoking, and oral contraceptive use? American Journal of Obstetrics and Gynecology 151(5): 612-616. Mar. 1, 1985.

88. CLELAND, J.G. and SATHAR, Z.A. The effect of birth spacing on childhood mortality in Pakistan. Population Studies 38(3): 401-418. Nov. 1984.

89. CLIQUET, R. and LODEWIJCKX, E. The contraceptive transition in Flanders. European Journal of Population 2(1): 71-84. May 1986.

90. COHEN, J. Clinical use of biphasic and triphasic pills. IPPF Medical Bulletin 19(4): 1-2. Aug. 1985.

91. COLLABORATIVE GROUP FOR THE STUDY OF STROKE IN YOUNG WOMEN. Oral contraceptives and stroke in young women: associated risk factors. Journal of the American Medical Association 231(7): 718-722. Feb. 17, 1975.

92. COLOMBIA. CENTRAL REGION CORPORATION OF POPULATION (CCRP). and INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE (DHS/IRD). Colombia Encuesta de Demografia y salud 1986: informe preliminar. [Colombia Demographic Health Survey 1986: preliminary report.] [SPA] Bogota, Colombia. and Columbia, Maryland, CCRP and DHS/IRD, Mar. 1987. 34 p.

93. COPPEN, A. and KESSEL, N. Menstruation and personality. British Journal of Psychiatry 109: 711-721. November 1963.

94. COSTA RICA DEMOGRAPHIC ASSOCIATION (CRDA). and UNITED STATES. CENTERS FOR DISEASE CONTROL (CDC). The Costa Rica Fertility and Health Survey, 1986. [San Jose,] Costa Rica and Atlanta, Georgia, CRDA, Sep. 1987. 100 p.

95. COY, J.F., MAIR, C.H., and RATKOWSKY, D.A. BREASTFEEDING and oral contracceptives: Tasmarian survey. Australian Paediatric Journal 19(3): 168-171. Sep. 1983.

96. CRAMER, D.W., GOLDMAN, M.B., SCHIFF, I., et al. The relationship of tubal infertility to barrier method and oral contraceptive use. Journal of the American Medical Association 257(18): 2446-2450. May 8, 1987.

97. CRAMER, D.W., HUTCHISON, G.B., WRLCH, W.R., SCULLY, R.E., and KNAPP, R.C. Factors affecting the association of oral contraceptives and ovarian cancer. New England Journal of Medicine 307(17): 1047-1051. Oct. 21, 1982.

98. CROFT, P. and HANNAFORD, P.C. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practioners' Oral Contraception Study. british Medical Journal 298: 165-168. Jan. 21, 1989.

99. CROOK, D., GODSLAND, I.F., and WYNN, V. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins. American Journal of Obstetrics and Gynecology 158(6, Pt.2): 1612-1620. Jun. 1988.

100. CROXATTO, H.B., DAZ, S., PERALTA, O., JUEZ, G., HERREROS, C., CASADO, M.E., SALVATIERRA, A.M., MIRANDA, P., and DURN, E. Fertility regulation in nursing women: 4. Long-term influence of a low-dose combined oral contraceptive initiated at day 30 postpartum upon lactation and infant growth. Contraception 27(1): 13-25. Jan. 1983.

101. CULLBERG, G., SAMSIOE, G., ANDERSEN, R.F., et al. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism: a comparative multicentre study on a triphasic and a fixec dose combination. Contraception 26(3): 229-243. Sep. 1982.

102. CULLBERG, J. Mental effects of hormone preparations with varied gestagen doses and constant oestrogen dose as compared to placedo. In: Psychosomatic medicine in obstetrics and gynaecology. Basel, Switzerland, Karger, 1972. p. 503-506.

103. CUZICK, J. Age dependence in cancers of the breast, ovary and endometrium. In: Likhachev, A., Anisimov, V., and Montesano, R., eds. Age-related factors in carcinogenesis. Lyon, France, World Health Organization. International Agency for Research on Cancer (IARC), 1685. (IARC Science Pub. No. 58) p. 97-104.

104. DARROW, W.W., BIGLER, W., DEPPE, D., FRENCH, J., GILL, P., POTTERAT, J., RAVENHOLT, O., SCHABLE, C., SIKES, R.K., and WOFSY, C. HIV antibody in 640 U.S. prostitutes with no evidence of intravenous (IV)-drug abuse. [Abstract] Presented at the 4th International Conference on AIDS, Stockholm, Sweden, Jun. 12-16, 1988.

105. DARROW, W.W., COHEN, J.B., FRENCH, J., GILL, P., SIKES, R.K., WITTE, J., et al. Multicenter study of HIV antibody in U.S. prostitutes. [Abstract] Presented at the 3rd International Conference on AIDS, Washington, D.C., Jun. 1-5, 1987.

106. DEL JUNCO, D.J. and ANNEGERS, J.F. Do oral contraceptives prevent rheumatoid arthritis? In reply. [Letter] Journal of the American Medical Association 256(2): 215-216. Jul. 11, 1986.

107. DERMAN, R. Oral contraceptives: assessment of benefits. Journal of Reproductive Medicine 31(9, Supp.): 879-886. Sep. 1986.

108. DIAZ, S., PERALTA, O., JUEZ, G., HERREROS, S., CASADO, }.E., SALVATIERRA, A.M., MIRANDA, P., DURN, E., and CROXATTO, H.B. Fertility regulation in nursing women: 3. Short-term influence of a low-dose combined oral contraceptive upon lactation and infant growth. Contraception 27(1): 1-11. Jan. 1983.

109. DICKEY, R. (Fertility Institute of New Orleans) [Multiphasic vs. monophasic OCs] Personal communication, Dec. 12, 1988.

110. DICKEY, R.P. Managing contraceptive pill patients. Durant, Oklahoma, Creative Informatics, 1987. 259 p.

111. DICKEY, R.P. Oral contraceptive user guide. Durant, Oklahoma, Infomatic Guides, 1987. 145 p.

* 112. DIONNE, P. and VICKERSON, F. A double-blind comparison of two oral contraceptives containing 50 micrograms and 30 micrograms ethinyl estradiol. Current Therapeutic Research, Clinical and Experimental 16(4): 281-288. Apr. 1974.

113. DJERASSI, C. The politics of contraception. New York, W.W. Norton, 1979. 274 p.

114. DOMINICAN REPUBLIC. CONSEJO NACIONAL DE POBLACION Y FAMILIA (CONAPOFA), and INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE (IRD). Encuesta Demografica y de Salud: DHS-86. [Dominican Republic Demographic and Health Survey: DHS-86.] [SPA] Santo Domingo, Dominican Republic and Columbia, Maryland, CONAPOFA and IRD, Dec. 1987. 139 p.

115. DORING, G., BAUR, S., FRANK, P., FREUNDL, G., and SOTTONG, U. Ergebnisse einer reprasentativen Umfrage zum Familie iplanungsverhalten in der Bundesrepublick Deutschland 1985. [Results of a representative survey of family planning behavior in the Federal Repubic of Germany.] [GER] Geburtshilfe and Frauenheilkunde 12(46): 857-920. Dec. 1986.

116. DRIFE, J. and GUILLEBAUD, J. Hormonal contraception and cancer. British Journal of Hospital Medicine 35(1): 25-29. Jan. 1986.

117. EARLY BREAST CANCER TRIALIST' COLLABORATIVE GROUP. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. New England Journal of Medicine 319(26): 1681-1692. Dec. 29, 1988.

118. EBELING, K. NISCHAN, P., and SCHINDLER, C., Use of oral contraceptives and risk of invasive cervical cancer in previously screened women. International Journal of Cancer 36(4): 427-430. 1987.

119. ECUADOR. CENTRO DE ESTUDIOS DE POBLACION Y PATERNIDAD RESPONSABLE (CEPAR), and INSTITUTO NACIONAL DE INVESTIGACIONES NUTRICIONALES Y MEDICO SOCIALES (ININMS). and INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE (IRD). Ecuador Encuesta Nacional de Demografia y Salud Familiar 1987: informe preliminar. [Ecuador Demographic and Health Survey 1987: preliminary report.] [SPA] [Quito], Ecuador and Columbia, Maryland, CEPAR, ININMS, and IRD, Jul. 1987. 25 p.

* 120. EDELMAN, D.A., KOTHENBEUTEL, R., LEVINSKI, M.J., and KELLY, S.E. Comparative trials of low-dose combined oral contraceptives. Journal of Reproductive Medicine 28(3): 195-200. Mar. 1983.

121. EDGREN, R.A. (Syntex Laboratories) [The comparative effects of currently and previously available oral contraceptive formulations] Personal communication, Feb. 21, 1989.

122. EGYPT. NATIONAL POPULATION COUNCIL (ENPC). and INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE (IRD/W). Egypt Demographic and Health Survey 1988: preliminary report. [Cairo], Egypt and [Columbia, Maryland], ENCP and IRD/W, Apr. 1989. 39 p.

123. EL SALVADOR. ASOCIACION DEMOGRAFICA SALVADORENA (ADS). and INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE (IRD). Encuesta National de Salud Familiar FESAL--85.[El Salvador National Survey of Family Health 1985.] [SPA] San Salvador, El Salvador and Columbia, Maryland, ADS and IRD, Sep. 1987. 179 p.

124. ELLERY, C., MACLENNAN, R., BERRY, G., and SHEARMAN, R.P. A case-control study of breast cancer in relation to the use of steroid contraceptive agents. Medical Journal of Australia 144(4): 173-176. Feb. 17, 1986.

125. ELLIS, V. (US Agency for Internatiol Development) [USAID OC Supplies, 1984-1987] Personal communication, May 10, 1989.

126. ELLSWORTH, H. Focus on Triphasil. Journal of Reproductive Medicine 31 (Supp. 6): 559-564. Jun. 1986.

127. EMMANUEL, S.C., LI, S.B., NG, T.P., and CHEN, A.J. Third National Family Planning and Population Survey. Singapore, Singapore Family Planning and Population Board, 1984. 83 p.

128. ESCHENBACH, D.A., HARNISH, J.P., and HOLMES, K.K. Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. American Journal of Obstetrics and Gynecology 128(8): 838-850. Aug. 15, 1977.

129. ESCOBEDO, L, and LEE, N.C. Beyond contraception: the health benefits and risks of the pill. IPPF Medical Bulletin 22(2): 1-2. Apr. 1988.

130. ESDAILE, J.M. and HORWITZ, R.I. Observational studies of cause-effect relationships: an analysis of methodologic problems as illustrated by the conflicting data for the role of oral contraceptives in the etiology of rheumatoid arthritis. Journal of Chronic Diseases 39(10): 841-852. 1986.

131. FASAL, E. anD PAFFENBARGER, R.S., Jr. Oral contraceptives as related to cancer and benign lesions of the breast. Journal of the National Cancer Institute 55(4): 767-773. Oct. 1975.

132. FAULKNER, W.L. anD ORY, H.W. Intrauterine devices and acute pelvic inflammatory disease. Journal of the American Medical Association 235(17): 1851-1853. Apr. 26, 1976.

133. FAY, R.A. Failure with the new triphasic oral contraceptive Logynon. British Medical Journal 284(6308): 17-18. Jan. 2, 1982.

134. FEDERMAN, D.D. General principles of endocrinology. In: Williams, R.H., ed. Textbook of endocrinology, 6th ed. Philadelphia, W.B. Saunders, 1981. p. 1-14.

135. FEINSTEIN, A.R. Scientific standards in epidemiologic studies kf the menace of daily life. Science 242(4883): 1257-1263. Dec. 2, 1988.

136. FELDBLUM, P.J., BURTON, N., and ROSENBERG, M.J. Pelvic inflammatory disease and oral contraceptive use. African Journal of Sexually Transmitted Diseases 2(2): 36-38. Oct. 1986.

137. FISCH, I.R. and FRANK, J. Oral contraceptives and blood pressure. Journal of the American Medical Association 237(23): 2499-2503. Jun. 6, 1977.

138. FISCH, I.R., FREEDMAN, S.H., and MYATT, A.V. Oral contraceptives, pregnancy, and blood pressure. Journal of the American Medical Association 222(12): 1507-1510. Dec. 18, 1972.

139. FISCHL, M., FAYNE, T., FLANAGAN, S., STEVENS, R., FLETCHER, M., LOVOIE, L., and TRAPIDO, E. Seroprevalence and risks of HIV infections in spouses of persons infected with HIV. [Abstract] Presented at the 4th International Conference on AIDS, Stockholm, Sweden, Jun. 12-16, 1988.

140. FISCHL, M.A., DICKINSON, G.M., FLANAGAN, S., and FLETCHER, M.A. Human immunodeficiency virus (HIV) among female prostitutes in south Florida. [Abstract] Presented at the 3rd International Conference on AIDS, Washington, D.C., Jun. 1-5, 1987.

141. FORMAN, D., VINCENT, T.J., and DOLL, R. Cancer of the liver and the use of oral contraceptives. British Medical Journal 292(6532): 1359-1361. May 24, 1986.

142. FORNARY, J. (International Planned Parenthood Federation) [IPPF OC Supples, 1982-1987] Personal communication, Jun. 9, 1989.

143. FORREST, J.D. Unintended pregnancy among American women. Family Planning Perspective 19(2): 76-77. Mar.-Apr. 1987.

* 144. FORREST, J.D. and FORDYCE, R.R. U.S. women's contraceptive attitudes and practice: how have they changed in the 1980s? Family Planning Perspective 20(3): 112-118. May-Jun. 1988.

145. FORTNEY, J.A. Contraception for women forty and over. Presented at the Annual Meeting of the Society for the Advancement of Contraception, Chicago, Sep. 23-26, 1986. 28 p.

146. FOSS, G.L. anD FOTHERBY, K. Clinical trial of a low dose combined oral contraceptive ("Ovranette"). Current Medical Research and Opinion 3(2): 72-76. 1975.

147. FOSS, G.L. and FOTHERBY, K. Low-oestrogen combined oral contraceptive. Acta European Fertilitatis 4:57-58. Jun. 1973.

148. FOTHERBY, K. Effect of oral contraceptives on serum lipids and cardiovascular disease. British Journal of Family Planning 11(3): 86-91. Oct. 1985.

149. FOTHERBY, K. Metabolic effects of low dose combined oral contraceptives. British Journal of Family Planning 10(1): 15-19. Apr. 1984.

150. FOTHERBY, K. Oral contraceptives, lipids and cardiovascular disease. Contraception 31(4): 367-394. Apr. 1985.

151. FRANCESCHI, S., LA VECCHIA, C., and TALAMINI, R. Oral contraceptives and cervical neoplasia: pooled information from retrospective and prospective epidemiologic studies. Tumori 72(1): 21-30. Feb. 28, 1986.

152. FRANK, P. Oral contraceptives and arterial disease--recent evidence from the Royal College of General Practitioners Oral Contraception Study. Singapore Journal of Obstetrics and Gynaecology 15(1, Supp.): 14-21. Mar. 1984.

* 153. FRASER, I.S. and JANSEN, R.P.S. Why do inadvertent pregnancies occur in oral contraceptive users? Effectiveness of oral contraceptive regimens and interfering factors. Contraception 27(6): 531-551. Jun. 1983.

* 154. FRASSINELLI-GUNDERSON, E.P., MARGEN, S., and BROWN, J.R. Iron stores in users of oral contraceptive agents. American Journal of Clinical Nutrition 41(4): 703-712. Apr. 1985.

155. GALFETTI, K.M. (The Pathfinder Fund) [Pathfinder OC supplies, 1982-1987] Personal communication, Jun. 9, 1989.

156. GASPARD, U.J., DEVILLE, J.L., and DUBOIS, M. Clinical experience with a triphasic oral contraceptive ("Trinordiol") in young women. Current Medical Research and Opinion 8(6): 395-404. 1983.

157. GASPARD, U.J., DUBOIS, M., GILLAIN, D., FRANCHIMONT, P., and DUVIVER, J. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Contraception 29(4): 305-318. Apr. 1984.

158. GERAIS, A.S., ALWAHAB, S., OMRAN, K.F., and LIAO, W.C. A comparative study of two estrogen dosages in combined oral contraceptives among Sudanese women. International Journal of Gynaecology and Obstetrics 21(6): 459-468. Dec. 1983.

159. GERAIS, A.S. and RUSHWAN, H. A crossover pill study among Sudanese women. International Journal of Gynaecology and Obstetrics 23: 229-233. 1985.

160. GIROLAMI, A., PROCIDANO, M., VICARIOTTO, M., CAPPELLATO, G., and VICARI, T. The effect of low-dose estroprogestinic preparations on prothrombin complex factors: no significant increase after an 8-month trial. Blut 50(3): 141-148. Mar. 1985.

161. GOEDERT, J.J., EYSTER, M.E., RAGNI, M.V., BIGGAR, R.J., and GAIL, M.H. Rate of heterosexual HIV transmission and associated risk with HIV-antigen. [Abstract] Presented at the 4th International Conference on AIDS, STockholm, Sweden, Jun. 12-16, 1988.

* 162. GOLDBAUM, G.M., KENDRICK, J.S., HOGELIN, G.C., GENTRY, E.M., and BEHAVIORAL RISK FACTOR SURVEYS GROUP. The relative impact of smoking and oral contraceptive use on women in the United States. Journal of the American Medical Association 258(10): 1339-1342. Sep. 11, 1987.

163. GOLDBERG, H.I., FRIEDMAN, J.S., WONG R., and RAJCOOMAR, V. Fertility and family planning in Mauritius. Presented at the Annual Meeting of the Population Association of America, San Francisco, Apr. 3-5, 1986. 23 p.

164. GOLDMAN, N., PEBLEY, A.R., WESTOFF, C.F., and PAUL, L.E. Contraceptive failure rates in Latin America. International Family Planning Perspective 9(2): 50-57. Jun. 1983.

165. GOLDMAN, N. and WESTOFF, C.F. Probabilities of conception in Latin America. 1982. 30 p. (Unpublished)

166. GONZALEZ, F. and MARKS, C. Hepatic tumors and oral contraceptives: surgical management. Journal of Surgical Oncology 29(3): 193-197. Jul. 1985.

167. GORDON, T., CASTELLI, W.P., HJORTLAND, M.C., KANNEL, W.B., and DAWBER, T.R. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. American Journal of Medicine 62(5): 707-714. May 1977.

168. GORRILL, M.J. and MARSHALL, J.R. Pharmacology of estrogens and estrogen-induced effects on nonreproductive organs and systems. Journal of Reproductive Medicine 31(9, Suppl.): 842-847. Sep. 1986.

169. GRADY, W.R., HAYWARD, M.D., and FLOREY, F.A. Contraceptive discontinuation among married women in the United States. Studies in Family Planning 19(4): 227-235. Jul.-Aug. 1988.

170. GRADY, W.R., HAYWARD, M.D., and YAGI, J. Contraceptive failure in the United States: estimates from the 1982 National Survey of Family Growth. Family Planning Perspective 18(5): 200-209. Sep.-Oct. 1986.

171. GRADY, W.R., HIRSCH, M.B., KEEN, N., and VAUGHAN, B. Contraceptive FAILURE AND CONTINUATION AMONG MARRIED WOMEN IN THE United States, 1970-75. STudies in Family Planning 14(1): 9-19. Jan. 1983.

172. GRAEFF, H., BATTIS, P., HAFTER, R., and ZANDER, J. Evaluation of hypercoagulability in users of oral contraceptives. Klinische Wochenschrift 55(4): 175-179. Feb. 15, 1977.

173. GRAHAM, H. Failure with the new triphasic oral contraceptive Logynon. [Letter] British Medical Journal 284(6313): 422. Feb. 6, 1982.

174. GRANT, J.P. The state of the world's children 1988. Oxford, Oxford University Press, 1988. 86 p.

175. GREENBLATT, R.M., LUKEHART, S.L., PLUMMER, F.A., QUINN, T.C., CRITCHLOW, C.W., D'COSTA, L.J., et al. Genital ulceration as a risk factor for human immunodeficiency virus infection in Kenya. [Abstract] Presented at the 3rd International Conference on AIDS, Washington, D.C., Jun. 1-5, 1987.

176. GREEP, R.O. The biological history of the pill. In: Parnham, M.J. and Bruinvels, J., eds. Discoveries in pharmacology. Vol. 2. Amsterdam, Elsevier Science Publishers, 1984. p. 321-337.

177. GRIMES, D.A. and HUGHES, J.M. Use of multiphasic oral contraceptives and hospitalizations of women with functional ovarian cysts in the United States. (To be published by Obstetrics and Gynecology)

178. GROOT, H. (Family Planning International assistance) [FPIA OC supplies, 1982-1987] Personal communication, Feb. 24, 1988.

179. GRUNENTHAL-SERVICE, THE. Internationaler Warenzeichen-Wegweiser fur hormonale Kontrazeptiva. _International directory for hormonal contraceptives.] [GER] [Tables] Stolberg, federal Republic of Germany, Burg Verlag & Druck, Nov. 1987. 125 p.

180. GUATEMALA, MINISTERIO DE SALUD PUBLIC Y ASISTENCIA SOCIAL (MSPAS). and INSTITUTO DE NUTRICION DE CENTRO AMERICA Y PANAMA (INCAP). and DEMOGRAPHIC AND HEALTH SURVEYS (DHS). INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE. Guatemala encuesta nacional de salud materno infantil: 1987: informe preliminar. [Guatemala: 1987 National Maternal and Child Health Survey: preliminary report.] [SPA] Guatemala City, Guatemala and Columbia, Maryland, MSPAS and INCAP and DHS, Mar. 1988. 26 p.

181. GUERRA, F., WARREN, C.W., OBERLE, M.W., and MORRIS, L. Maternal-child health/family planning survey: Panama 1984. Atlanta, Georgia, Centers for Disease Control, Mar. 1986. 140 p.

182. GUILLEBAUD, J. The 150/30 formulation experience in the \nited Kingdom. Journal of Reproductive medicine 28(Suppl. 1): 66-70. Jan. 1983.

183. GUILLEBAUD, J. The forgotten pill--and the paramount importance of the pill-free week. British Journal of Family Planning 12(4): 35-43. Jan. 1987.

184. GUILLEBAUD, J. The pill. 2n ed. Oxford, Oxford University Press, 1983. 278 p.

* 185. GUILLEBAUD, J. Practical prescribing of the combined oral contraceptive pill. In: Filshire, M. and Guillebaud, J., eds. Science and practice. Guildford, Surrey, UK, Butterworths, 1989. (In press)

186. HACETTEPE UNIVERSITY. INSTITUTE OF POPULATION STUDIES (IPS). 1983 Turkish population and health survey. Ankara, Turkey, IPS, 1987. 130 p.

187. HANSON, F.W. and NISWANDER, K.R. A new low dose norethindrone acetate (0.6 mg) ethinyl estradiol (30 mcg) combination oral contraceptive. Journal of Reproductive Medicine 12(3): 109-111. Mar. 1974.

188. HARFOUCHE, J.K. Appearance of contraceptive steroids in human milk: effects on the child. Journal of Biosocial Science (Suppl. 4): 165-179. 1977.

189. HARLAP, S. HIV and fertility regulation. 1987. 265 p. (Unpublished)

190. HARRIS, R.W., BRINTON, L.A., COWDELL, R.H., SKEGG, D.C., SMITH, P.G., VESSEY, M.P., and DOLL, R. Characteristics of women with dysplasia or carcinoma in situ of the cervix uteri. British Journal of Cancer 42:359-369. 1980.

191. HARRISON, H.R., COSTIN, M., MEDER, J.B., BOWNDS, L.M., SIM, D.A., LEWIS, M., and ALEXANDER, E.R. Cervical Chlamydia trachomatis infection in university women: relationship to history, contraception, ectopy, and cervicitis. American Journal of Obstetrics and Gynecology 153(3): 244-251. Oct. 1, 1985.

192. HARVENGT, C., DESAGER, J.P., GASPARD, U., and LEPOT, M. Changes in lipoprotein composition in women receiving two low-dose oral contraceptives containing ethinylestradiol and gonane progestins. Contraception 37(6): 565-575. Jun. 1988.

193. HASPELS, A.A. Clinical experience with a low-dose contraceptive agent: European studies. Journal of Reproductive Medicine 28(Suppl. 1): 71-76. Jan. 1983.

194. HATCHER, R.A., GUEST, F., STEWART, F., STEWART, G.K., TRUSSELL, J., CEREL, S., and CATES, W. Contraceptive technology 1986-1987. 13th rev. ed. New York, Irvington Publishers, 1986. 310 p.

195. HATCHER, R.A., GUEST, F., STEWART, F., STEWART, G.K., TRUSSELL, J., BOWEN, S.C., and CATES, W. Contraceptive technology 1988-1989. 14th rev. ed. Atlanta, Georgia, Printed Matter, 1988. 437 p.

196. HAZES, J.M. and DIJKMANS, B.A. Do oral contraceptives prevent rheumatoid arthritis? [Letter] Journal of the American Medical Association 256(2): 215. Jul. 11, 1986.

197. HEATH, K., DA COSTA-MARTINEZ, D., and SHEON, A.R. Trinidad and Tobago: demographic and health survey 1987. Port-of-Spain. Trinidad and Columbia, Maryland, Family Planning Association of Trinidad and Tobago and Institute for Resource Development/Westinghouse, Nov. 1988. 134 p.

198. HELLBERG, D., VALENTIN, J., and NILSSON, S. Long-term use of oral contraceptives and cervical neoplasia: an association confounded by other risk factors? Contraception 32(4): 337-346. Oct. 1985.

199. HELMRICH, S.P., ROSENBERG, L., KAUFMAN, D.W., STROM, B., and SHAPIRO, S. Venous thromboembolism in relation to oral contraceptive use. Obstetrics and Gynecology 69(1): 91-95. Jan. 1987.

200. HELMRICH, S.P., ROSENBERG, L., KAUFMAN, D.W., MILLER, D.R., SCHOTTENFELD, D., STOLLEY, P.D., and SHAPIRO, S. Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. Journal of the National Cancer Institute 72(3): 617-620. Mar. 1984.

201. HENDERSON, B.E., CASAGRANDE, J.T., PIKE, M.C., MACK, T., ROSARIO, I., and DUKE, A. The epidermiology of endometrial cancer in young women. British Journal of Cancer 476(6): 749-756. Jun. 1983.

202. HENDERSON, B.E., PRESTON-MARTIN, S., EDMONDSON, H.A., PETERS, R.L., and PIKE, M.C. Hepatocellular carcinoma and oral contraceptives. British Journal of Cancer 48(3): 437-440. Sep. 1983.

203. HENNEKENS, C.H., SPEIZER, F.E., LIPNICK, R.J., ROSNER, B., BAIN, C., BELANGER, C., STAMPFER, M.J., WILLETT, W., and PETO, R. A case-control study of oral contraceptive use and breast cancer. Journal of the National Cancer Institute 72(1): 39-42. Jan. 1984.

204. HENNEY, J.E. and DEVITA, V.T., Jr. Breast cancer. In: Petersdorf, R.G., Adams, R.D., Braunwald, E., Isselbacher, K.J., Martin, J.B., and Wilson, J.D., eds. Harrison's principles of internal medicine. 10th ed. New York, McGraw-Hill, 1983. p. 788-795.

205. HENSHAW, S.K. and MARTIRE, G. Abortion and the public opinion polls. Family Planning Perspectives 14(2): 53-55, 59-62. Mar.-Apr. 1982.

206. HILDRETH, N.G., KELSEY, J.L., LIVOLSI, V.A., FISCHER, D.B., HOLFORD, T.R., MOSTOW, E.D., SCHWARTZ, P.E., and WHITE, C. An epidemiologic study of epithelial carcinoma of the ovary. American Journal of Epidemiology 114(3): 398-405. Sep. 1981.

207. HILL, A.B. Statistical evidence and inference. In: Principles of medical statistics. 9th ed. New York, Oxford University Press, 1971. p. 309-323.

208. HIRA, S.K., KAMANGA, J., MACUACUA, R., and PERINE, P. Oral contraceptive use and HIV infection. [1988]. 2 p. (Unpublished)

209. HOBCRAFT, J., MCDONALD, J., and RUSTEIN, S. Childspacing effects infant and early child mortality. Population Index 49(4): 585-618. Winter 1983.

210. HOLCK, S. Cancer and the pill. World Health, Nov. 1987. p. 18-19.

* 211. HOLCK, S. Hormonal contraceptives and the risk of cancer. World Health Statistics Quarterly 40(3): 225-232. 1987.

212. HOLLY, E.A., WEISS, N.S., and LIFF, J.M. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. Journal of the National Cancer Institute 70(5): 827-831. May 1983.

213. HOLMES, K.K. Pelvic inflammatory disease. In: Petersdorf, R.G., Adams, R.D., Braunwald, E., Isselbacher, K.J., Martin, J.B., and Wilson, J.D., eds. Harrison's principles internal medicine. 10th ed. New York, McGraw-Hill, 1983. p. 902-908.

214. HONDURAS. MINISTRY OF PUBLIC HEALTH (HMPH). and ASSOCIATION FOR FAMILY PLANNING IN HONDURAS (ASHONPLAFA). Maternal-child health and family planning survey: Honduras, 1984: Final report. [Tegucigalpa, Honduras], HMPH and ASHONPLAFA, Dec. 1986. 202 p.

215. Hopflinger, F. and KUHNE, F. Contraception: answers of wives and husbands compared in a survey of Swiss couples. Journal of Biosocial Science 16(2): 259-268. Apr. 1984.

* 216. HOWIE, P.W. The progestogen-only pill. British Journal of Obstetrics and Gynaecology 92(10): 1001-1002. Oct. 1985.

217. HUBER, D.H., KHAN, A.R., BROWN, K., MALAKAR, M., and SAIT, G. Oral and injectable contraceptives--the effects on breast-milk and child growth in Bangladesh. Feb. 1980. 22 p. (Unpublished)

218. HUGGINS, G.R. and ZUCKER, P.K. Oral contraceptives and neoplasia: 1987 update. Fertility and Sterility 47(5): 733-761. May 1987.

219. HUGHES, I. An open assessment of a new low dose oestrogen combined oral conraceptive. Journal of International Medical Research 6(1): 41-45. 1978.

220. HULKA, B.S., CHAMBLESS, L.E., KAUFMAN, D.G., FOWLER, W.C., Jr., and GREENBERG, B.G. Protection against endometrial carcinoma by combination-product oral contraceptives. Journal of the American Medical Association 247(4): 475-477. Jan. 22-29, 1982.

221. HULKA, B.S., KAUFMAN, D.G., FOWLER, W.C., Jr., GRIMSON, R.C., and GREENBERG, B.G. Predominance of early endometrial cancers after long-term estrogen use. Journal of the American Medical Association 244(21): 2419-2422. Nov. 28, 1980.

222. HULL, V.J. The effects of hormonal contraceptives on lactation: current findings, methological considerations, and future priorities. Studies in Family Planning 12(4): 134-155. Apr. 1981.

223. HUNGARY. CENTRAL STATISTICAL OFFICE (CSO). Summary of the 1986 fertility Surveys. Budapest, CSO, 1987. 21 p.

224. IMS LTD. Purchases of oral contraceptives. [Study prepared for the Population Information Program] May 1988. 116 p.

225. INDONESIA. CENTRAL BUREAU OF STATISTICS (CBS). and NATIONAL FAMILY PLANNING COORDINATING BOARD (NFPCB). and INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE (IRD). National Indonesia Contraceptive Prevalence Survey 1987. Jakarta and Columbia, Maryland, CBS, NFPCB, and IRD, Jan. 1989. 137 p.

226. INMAN, W.H.W. Oral contraceptives and fatal subarachnoid haemorrhage. British Medical Journal 2(6203): 1468-1470. Dec. 8, 1979.

227. INMAN, W.H.W., VESSEY, M.P., WESTERHOLM, B., and ENGELUND, A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. British Medical Journal 2(5703): 203-209. Apr. 25, 1970.

228. INTERCONTINENTAL MEDICAL STATISTICS (IMS) AMERICA LTD. Purchases of oral contraceptives. [Study prepared for the Population Information Program] Oct. 1981. 3 p.

229. INTERCONTINENTAL MEDICAL STATISTICS (IMS) INTERNATIONAL LTD. Retail pharmacy purchases of oral contraceptives and components of oral contraceptives. [Study prepared for the Population Information Program] Nov. 1977 and Nov. 1978. 2 p.

230. INTERCONTINENTAL MEDICAL STATISTICS (IMS). Retail pharmacy purchases of oral contraceptives and components of oral contraceptives. [Study prepared for the Population Information Program] Oct. 1978. 1 p.

231. INTERNATIONAL PLANNED PARENTHOOD FEDERATION. IPPF statement on sexually transmitted diseases and reproductive health. IPPF Medical Bulletin 22(6): 3-4. Dec. 1988.

232. INTERNATIONAL PLANNED PARENTHOOD FEDERATION. Statement on breast feeding, fertility and contraception. IPPF Medical Bulletin 21(6): 5-6. Dec. 1987.

233. IRWIN, K.L., ROSERO-BIXBY, L., OBERLE, M.W., LEE, N.C., WHATLEY, A.S., FORTNEY, J.A., and BONHOMME, M.G. Oral contraceptives and cervical cancer risk in Costa Rica: detection bias or causal association? Journal of the American Medical Association 259(1): 59-64. Jan. 1, 1988.

234. ISHAK, R., HASSAN, K., and ARSHAT, H. Hemorrheology and fibrinolytic response in women taking oral contraceptive pills. Malaysian Journal of Reproductive Health 5(2): 57-60. Dec. 1987.

235. JAGDEO, T.P. Contraceptive prevalence in Montserrat. New York, International Planned Parenthood Federation, Western Hemisphere Region, 1985. (IPPF/WHR Caribbean Contraceptive Prevalence Surveys No. 2) 152 p.

236. JAGDEO, T.P. Contraceptive prevalence in St. Kitts-Nevis. New York, International Planned Parenthood Federation, Western Hemisphere Region, 1985. 126 p.

237. JAGDEO, T.P. Contraceptive prevalence in Grenada. New York, International Planned Parenthood Federation, Western Hemisphere Region, 1987. (IPPF/WHR Caribbean Contraceptive Prevalence Surveys No. 3) 169 p.

238. JANOWITZ, B., BAILEY, P., OCHOA, J., and SUAZO, M. Contraceptive use and fertility in Honduras, 1981-84. Studies in Family Planning 18(5): 291-301. Sep.-Oct. 1987.

239. JELLIFFE, D.B. and JELLIFFE, E.F. Lactation amenorrhoea: an important present-day component of family planning programmes. Journal of Tropical Pediatrics 31(5): 240-241. Oct. 1985.

240. JICK, H., PORTER, J., and ROTHMAN, K.J. Oral contraceptives and nonfatal stroke in healthy young women. Annals of Internal Medicine 89(1): 58-60. Jul. 1978.

241. JICK, S.S., WALKER, A.M., STERGACHIS, A., and JICK, H. Oral contraceptives and breast cancer. British Journal of Cancer 59(4): 618-621. Apr. 1989.

242. JOHNSON, S.R. The epidemiology and social impact of premenstrual symptoms. Clinical Obstetrics and Gynecology 30(2): 367-376. Jun. 1987.

243. JONES, E.F. The availability of contraceptive services. Voorburg, Netherlands, International Statistical Institute, Jul. 1984. (WFS Comparative Studies No. 37) 99 p.

244. JONES, H.W., 3rd. Cervical intraepithelial neoplasia. In: Jones, H.W., 3rd, Wentz, A.C., and Burnett, L.S. Novak's Textbook of Gynecology. 11th ed. Baltimore, Williams & Wilkins, 1988. p. 643-678.

245. JONES, H.W., 3rd. Epithelial ovarian cancer. In: Jones, H.W., 3rd, Wentz, A.C., and Burnett, L.S. Novak's Textbook of Gynecology. 11th ed. Baltimore, Williams & Wilkins, 1988. p. 792-830.

246. JONES, H.W., 3rd. Invasive cancer of the cervix. In: Jones, H.W., 3rd, Wentz, A.C., and Burnett, L.S. Novak's Textbook of Gynecology. 11th ed. Baltimore, Williams & Wilkins, 1988. p. 679-715.

247. JUDD, H.L. and MELDRUM, D.R. Physiology and pathophysiology of menstruation and menopause. In: Romney, S.L., Gray, M.J., Little, A.B., Merrill, J.A., Quilligan, E.J., and Stander, R.W. Gynecology and obstetrics: the health care of women. 2nd ed. New York, McGraw-Hill, 1981. p. 885-907.

248. JUDD, S.J. and KERIN, J. Contraception and diabetes mellitus. Clinical Reproduction and Fertility 4(5): 297-304. Oct. 1986.

249. KALLIO, H. and RHEN, K. The contraceptive effects of a new low-dose combination type oral contraceptive. Current Medical Research and Opinion 5(6): 444-449. 1978.

250. KAMNUANSILPA, P. and CHAMRATRITHIRONG, A. Contraceptive use and fertility in Thailand: results from the 1984 Contraceptive Prevalence Survey. Bangkok, National Institute of Development Administration, Research Center; Mahidol University, Institute for Population and Social Research; and Ministry of Public Health, National Family Planning Program, 1985. 154 p.

251. KAUFMAN, D.W., SHAPIRO, S., SLONE, D., ROSENBERG, L., }IETTINEN, O.S., STOLLEY, P.D., KNAPP, R.C., LEAVITT, T., Jr., WATRING, W.G., and ROSENSHEIN, N.B. Decreased risk of endometrial cancer among oral-contraceptive users. New England Journal of Medicine 303(18): 1045-1047. Oct. 30, 1980.

252. KAY, C.R. Malignant melanoma and oral contraceptives. [Letter] British Journal of Cancer 44(3): 479. Sep. 1981.

* 253. KAY, C.R. Progestogens and arterial disease--evidence from the Royal College of General Practitioners' study. American Journal of Obstetrics and Gynecology 142(6, Pt. 2): 762-765. Mar. 15, 1982.

254. KAY, C.R. and HANNAFORD, P.C. Breast cancer and the pill--a furter report from the Royal College of General Practitioners' Oral Contraception Study. British Journal of Cancer 58: 675-680. 1988.

255. KELSEY, J.L. and BERKOWITZ, G.S. Breast cancer epidemiology. Cancer Research 48(20): 5615-5623. Oct. 15, 1988.

256. KELSEY, J.L., LIVOLSI, V.A., HOLFORD, T.R., FISCHER, D.B., MOSTOW, E.D., SCHWARTZ, P.E., O'CONNOR, T., and WHITE, C. A case-control study of cancer of the endometrium. American Journal of Epidemiology 116(2): 333-42. Aug. 1982.

257. KENDRICK, J.S. and ORY, R.W. Risks and benefits of using oral contraceptives. Presented at the 7th European Sterility Congress, }ojte Carlo, Sep. 1984. 13 p.

258. KENNEDY, K.I., RIVERA, R., and MCNEILLY, A.S. Consensus statement on the use of breastfeeding as a family planning method. Presented at the Bellagio Consensus Conference on Lactational Infertility, Bellagio, Italy, Aug. 1988. 18 p. (To be published by Contraception)

259. KETTING, E. The relative reliability of oral contraceptives; findings of an epidemiological study. Contraception 37(4): 343-348. Apr. 1988.

260. KHAW, K.-T. and PEART, W.S. Blood pressure and contraceptive; use. British Medical Journal 285(6339): 403-407. Aug. 7, 1982.

261. KHOO, S.K. Cancer risks and the contraceptive pill: what is the evidence after nearly 25 years of use? Medical Journal of Australia 144(4): 185-190. Feb. 17, 1986.

262. KISTNER, R.W. The oviduct. In: Gynecology principles and practice. 4th ed. Chicago, Year Book Medical Publishers, 1986. p. 249-287.

263. KLEINBERG, D.L. Prolactin and breast cancer. New England Journal of medicine 316(5): 269-271. Jan. 29, 1987.

264. KOETSAWANG, S. The effects of contraceptive methods on the quality and quantity of breast milk. International Journal of Gynecology and Obstetrics 25 (Suppl.): 115-127. 1987.

265. KOETSAWANG, S. and SRISUPANDIT, S. Clinical trial of low-dose oral contraceptive pill containing 0.75 mg. lynestrenol and 0.0375 mg. ethinyl estradiol. Journal of the Asian Federation of Obstetrics and Gynecology 5(4): 28-32. Jul. 1977.

266. KOUTSKY, L.A., GALLOWAY, D.A., and HOLMES, K.K. Epidemiology of genital human papillomavirus infection. Epidemiologic Reviews 10: 122-163. 1988.

267. KRUEGER, D.E., ELLENBERG, S.S., BLOOM, S., et al. Fatal myocardial infarction and the role of oral contraceptives. American Journal of Epidemiology 111(6):655-674. Jun. 1980.

268. KUHNE, F. Kontrazeption in der Schweiz. [Contraception in Switzerland: a sociological study of contraceptive usage and attitudes toward abortion among Swiss married couples.] [SWI] Hedingen, Switzerland, Franz Kuhne, 1984. 339 p.

269. KUTNER, S.J. and BROWN, W.L. Types of oral contraceptives, depression, and premenstrual symptoms. Journal of Nervous and Mental Disease 155(3): 153-162. Sep. 1972.

270. LA ROSA, J.C. Atherosclerotic risk factos in cardiovascular disease. Journal of Reproductive Medicine 31(9, Suppl.): 906-912. Sep. 1986.

271. LA VECCHIA, C., DECARLI, A., FASOLI, M., FRANCESCHI, S., GENTILE, A., NEGRI, E., PARAZZINI, F., and TOGNONI, G. Oral contraceptives and cancers of the breast and of the female genital tract: interim results from a case-control study. British Journal of Cancer 54(2): 311-317. Aug. 1986.

272. LABBOK, M.H. Contraception during lactation: considerations in advising the individual and in formulating programme guidelines. Journal of Biosocial Science 9(Suppl.): 55-66. 1985.

* 273. LAING, J.E. Continuation and effectiveness of contraceptive practice: a cross-sectional approach. Studies in Family Planning 16(3): 138-153. May-Jun. 1985.

274. LANDGRAN, B.-M. and DICZFALUSY, E. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles. Contraception 29(5): 437-446. May 1984.

* 275. LAUKARAN, V.H. Contraceptive choices for lactating women: suggestions for postpartum family planning. Studies in Family Planning 12(4): 156-163. Apr. 1981.

276. LAW, C. The male factor in human papillomavirus infection and cervical malignancy. Healthright 7(1): 14-17. Nov. 1987.

277. LAWSON, J.S., YULIANO, S.E., PASQUALE, S.A., and OSTERMAN, J.J. Optimum dosage of an oral contraceptive: a report from the study of seven combinations of norgestimate and ethinyl estradiol. American Journal of Obstetrics and Gynecology 134(3): 315-320. Jun. 1, 1979.

* 278. LAYDE, P.M., BERAL, V., and KAY, C.R. Further analyses of mortality in oral contraceptive users: Royal College of general Practitioners' Oral Contraception Study. Lancet 1(8219): 541-546. Mar. 7, 1981.

* 279. LAYDE, P.M., ORY, H.W., BERAL, V., and KAY, C.R. Incidence of arterial disease among oral contraceptive users: Royal College of General Practitioners' Oral Contraception Study. Journal of the Royal Colle of General Practitioners 33-(247): 75-82. Feb. 1983.

280. LE, M.-G., BACHELOT, A., DOYON, F., KRAMAR, A., and HILL, C. Oral contraceptive use and breast or cervical cancer: preliminary results of a French case-control study. In: Wolff, J.-P. and Scott, J.S., eds. Hormones and sexual factors in human cancer aetiology. Amsterdam, Excerpta Medica, 1984. p. 139-147.

281. LEE, N.C., ROSERO-BIXBY, L., OBERLE, M.W., GRIMALDO, C., WHATLEY, A.S., and ROVIRA, E.Z. A case-control study of breast cancer and hormonal contraception in costa Rica. Journal of the National Cancer Institute 79(6): 1247-1254. Dec. 1987.

282. LEES, A.W., BURNS, P.E., and GRACE, M. Oral contraceptives and breast disease in premenopausal northern Albertan women. International Journal of Cancer 22(6): 700-707. Dec. 15, 1978.

283. LERIDON, H. and TOULEMON, L. La contraception en France: pilule et sterilet. [Contraception in France: pills and sterilization.] [FRE] Population and Societes 228: 1-4. Oct. 1988.

284. LINOS, A., O'FALLON, W.M., WORTHINGTON, J.W., and KURLAND, L.T. Case-control study of rheumatoid arthritis and prior use of oral contraceptives. Lancet 1(8337): 1299-1300. Jun. 11, 1983.

285. LIPNICK, R.J., BURING, J.E., HENNEKENS, C.H.M ROSNER B., WILLETT, W., BAIN, C., STAMPFER, M.J., COLDITZ, G.A., PETO, R., and SPEIZER, F.E. Oral contraceptives and breast cancer: a prospective cohort study. Journal of the American Medical Association 255(1): 58-61. Jan. 3, 1986.

286. LIPSETT, M.B. and LIPPMAN, M.E. Endocrine responsive cancers of man. In: Williams, R.H., ed. Textbook of endocrinology. 6th ed. Philadelphia, W.B. Saunders, 1981. p. 1213-1227.

287. LOBO, R.A. Lipids, clotting factors, and diabetes: endogenous risk factors for cardiovascular disease. American Journal of Obstetrics and Gynecology 158(6, Supp. 2): 1584-1591. Jun. 1988.

* 288. LONDON, J., CUSHING, J., CLELAND, J., ANDERSON, J.E., MORRIS, L., MOORE, S.H., and RUTSTEIN, S.O. Fertility and family planning surveys: an update. Population Reports, Series M, No. 8. Baltimore, Johns Hopkins University, Population Information Program, Sep.-Oct. 1985. 60 p.

289. LONGSTRETH, W.T., Jr., KOEPSELL, T.D., YERBY, M.S., and VAN BELLE, G. Risk factors for subarachnoid hemorrhage. Stroke 16(3): 377-385. May-Jun. 1985.

* 290. LONGSTRETH, W.T. and SWANSON, P.D. Oral contraceptives and stroke. Stroke 15(4): 747-750. Jul-Aug. 1984.

291. LOUV, W.C., AUSTIN, H., PERLMAN, J., and ALEXANDER, W.J. Oral contraceptive use and the risk of chlamydial and gonococcal infections. American Journal of Obstetrics and Gynecology 160(2): 396-402. Feb. 1989.

292. LYON, J.L., GARDNER, J.W., WEST, D.W., STANISH, W.M., and HEBERTSON, R.M. Smoking and carcinoma in situ of the uterine cervix. American Journal of Public Health 73(5): 558-562. May 1983.

293. MACDONALD, H.N. Smoking and oral contraception in cancer of the cervix. [Letter] Lancet 2(8305): 989. Oct. 30, 1982.

294. MACMAHON B., COLE, P., LIN, T.M., LOWE, C.R., MIRRA, A.P., RAVNIHAR, B., SALBER, E.J., VALAORAS, V.G., and YUASA, S. Age at first birth and breast cancer risk. Bulleting of the World Health Organization 43(2): 209-221. 1970.

295. MACMAHON, B. and PUGH, T.F. Epidemiology: principles and methods. Boston, Little, Brown, 1970. 376 p.

* 296. MANN, J.I. Progestogens in cardiovascular disease: an introduction to the epidemiologic data. American Journal of Obstetrics and Gynecology 142(6, Pt. 2): 752-757. Mar. 15, 1982.

* 297. MANN, J.I. and INMAN, W.H.W. Oral contraceptives and death from myocardial infarction. British Medical Journal 2(5965): 245-248. May 3, 1975.

* 298. MANN, J.I., VESSEY, M.P. THOROGOOD, M., and DOLL, R. Myocardial infarction in young women with special reference to oral contraceptive practice. British Medical Journal 2(5965): 241-245. May 3, 1975.

299. MASER, J. Triphasic oral contraceptives. On Continuing PRactice 10(2): 7-9. Apr. 1983.

300. MASIRONI, R. and ROTHWELL, K. Smoking in developing countries (3). Geneva, World Health Organization, 1985. 56 p. (Mimeo)

301. MASSIL, H.Y. and O'BRIEN, P.M.S. Approach to the management of premenstrual and syndrome. Clinical Obstetrics and Gynecology 30(2): 443-452. Jun. 1987.

302. MAUSNER, J.S. and BAHN, A.K. Epidemiology: an introductory text. Philadelphia, W.B. Saunders, 1974. 377 p.

303. MCCANN, M.F. The effect of a progestogen-only oral contraceptive (lynestrenol 0.5 mg) on lactation. Presented at a Symposium on Lactation and Birthspacing, Mexico city, Mexico ,Aug. 8, 1984. 18 p.

* 304. MCCANN, M.F., LISKIN, L.S., PIOTROW, P.T., RINEHART, W., and FOX, G. Breast-feeding, fertility, and family planning. Population Reports, Series J, No. 24. Baltimore, Johns Hopkins University, Population Information Program, Mar. 1984 (Rev.) 52 p.

305. MCGOWAN, L., PARENT, L., LEDNAR, W., And NORRIS, H.J. The woman at risk for developing ovarian cancer. Gynecologic Oncology 7(3): 325-344. Jun. 1979.

306. MCLAUGHLIN, L. The pill, John Rock, and the church: the biography of a revolution. Boston, Little, Brown, 1982. 243 p.

307. MCPHERSON, K. Latent effect of oral contraceptives on breast cancer. Journal of the American Medical Association 260(9): 1240-1241. Sep. 2, 1988.

* 308. MCPHERSON, K. and DRIFE, J.O. The pill and breast cancer: why the uncertainty? British Medical Journal 293(6549): 709-710. Sep. 20, 1986.

309. MCPHERSON, K., NEIL, A., VESSEY, M.P., and DOLL, R. Oral contraceptives and breast cancer. [Letter] Lancet 2(8364): 1414-1415. Dec. 17, 1983.

* 310. MCPHERSON, K., VESSEY, M.P., NEIL, A., DOLL, R., JONES, L., and ROBERTS, M. Early oral contraceptive use and breast cancer: results of another case-control study. British Journal of Cancer 56(5): 653-660. November 1987.

311. MCTIERNAN, A. and THOMAS, D.B. Evidence for a protective effect of lactation on risk of breast cancer in young women. American Journal of Epidemiology 124(3): 353-358. Sep. 1986.

312. MEADE, T.W. Effects of progestogens on the cardiovascular system. American Journal of Obstetrics and Gynecology 142(6, Pt. 2): 776-780. Mar. 15, 1982.

* 313. MEADE, T.W., GREENBERG, G., and THOMPSON, S.G. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-[mu]g oestrogen preparations. British Medical Journal 280(6224): 1157-1161. May 10, 1980.

314. MEARS, E. and GRANT, E.C. "Anovlar" as an oral contraceptive. British Medical Journal 2: 75-79. Jul. 14, 1962.

315. MEASHAM, A.R., KHAN, A.R., MEASHAM, C.D., KHANUM, F., and AKBAR, J. Use-effectiveness of standard-dose and low-dose oral contraceptives in Dacca. International Journal of Gynaecology and Obstetrics 18(5): 354-356. 1980.

* 316. MEIRIK, O. and FARLEY, T.M.M. Evidence that contraceptives such as OCs affect HIV transmission. Jan. 31, 1989. 11 p. (Unpublished)

317. MEIRIK, O., FARLEY, T.M.M., LUND, E., ADAMI, H.-O., CHRISTOFFERSEN, T., and BERGSJO, P. Breast cancer and oral contraceptives: patterns of risk among parous and nulliparous women--further analysis of the Swedish-Norwegian material. Contraception 39(5): 071-475. May 1989.

318. MEIRIK, O., LUND, E., ADAMI, H.-O., BERGSTROM, R., CHRISTOFFERSENN, T., and BERGSJO, P. Oral contraceptive use and breast cancer in young women: a joint national case-control study in Sweden and Norway. Lancet 2(8508): 650-664. Sep. 20, 1986.

319. MELBYE, M., NJELESANI, E.K., BAYLEY, A., MUKELABAI, K., MANUWELE, J.K., BOWA, F.J., CLAYDEN, S.A., LEVIN, A., BLATNER, W.A., WEISS, R.A., TEDDER, R., and BIGGAR, R.J. Evidence for heterosexual transmission and clinical manifestations of human immunodeficiency virus infection and related conditions in Lusaka, Zambia. Lancet 2(8516): 1113-1115. Nov. 15, 1986.

320. MILLER, A.B. and BULBROOK, R.D. UICC multidisciplinary project on breast cancer: the epidemiology, aetiology and prevention of breast cancer. International Journal of Cancer 37(2): 173-177. Feb. 1986.

321. MILLER, D.R., ROSENBERG, L., KAUFMAN, D.W., SCHOTTENFELD, D., STOLLEY, P.D., and SHAPIRO, S. Breast cancer risk in relation to early oral contraceptive use. Obstetrics and Gynecology 68(6): 863-868. Dec. 1986.

* 322. MILLER, D.R., ROSENBERG, L., KAUFMAN, D.W., STOLLEY, P., WARSHAUER, M.E., and SHAPIRO, S. Breast cancer before age 45 and oral contraceptive use: new findings. American Journal of Epidemiology 129(2): 269-280. Feb. 1989.

323. MILLER, L.G. Update on the new triphasic oral contraceptives. [Letter] Clinical Pharmacy 4(1): 24-25. Jan.-Feb. 1985.

324. MISHELL, D.R. Noncontraceptive health benefits of oral steroidal contraceptives. American Journal of Obstetrics and Gynecology 142(6, Pt. 2): 809-816. Mar. 15, 1982.

* 325. MISHELL, D.R., Jr. Use of oral contraceptives in women of older reproduction age. American Journal of Obstetrics and Gynecology 158(6, Pt. 2): 1652-1657. Jun. 1988.

326. MOGGIA, A.V. Contraception with levonorgestrel, 0.15 mg, and ethinyl estradiol, 0.03 mg.: clinical studies in Latin America. Journal of Reproductive Medicine 28(Suppl. 1): 77-80. Jan. 1983.

327. MOLLOY, B.G., COULSON, K.A., LEE, J.M., and WATTERS, J.K. "Missed pill" conception: fact or fiction? British Medical Journal 290(6480): 1474-1475. May 18, 1985.

328. MONTEITH, R.S., ANDERSON, J.E., MASCARIN, F., and MORRIS, L. Contraceptive use and fertility in the Republic of Panama. Studies in Family Planning 12(10): 331-340. Oct. 1981.

329. MONTEITH, R.S., ANDERSON, J.E., PINEDA, M.A., SANTISO, R., and OBERLE, M. Contraceptive use and fertility in Guatemala. Studies in Family Planning 16(5): 279-288. Sept.-Oct. 1985.

330. MOOS, R.H. Psychological aspects of oral contraceptives. Archives of General Psychiatry 19: 87-94. Jul. 1968.

331. MORENO A., J. and ROWAN, A.J. A comparative study of Norinyl 1/35 versus Brevicon in Panama City, Panama. Contraception 36(6): 615-625. Dec. 1987.

332. MORIGI, E.M. and PASQUALE, S.A. Clinical experience with a low dose oral contraceptive containing norethisterone and ethinyl oestradiol. Current Medical Research and Opinion 5(8): 655-662. 1978.

333. MOROCCO. MINISTERE DE LA SANTE PUBLIQUE (MSP). Enquete nationale sur la fecondite et la planification familiale au Maroc 1979-80. Rapport national. Vol. 1--presentation du pays et methodologie de l'enquete. [Morocco National Fertility and Family Planning Survey, 1979-80. National report. Vol. 1--country presentation and survey methodlogy.] [FRE] [Rabat, Morocco], MSP, 1984. 181 p.

334. MOROCCO. MINISTERE DE LA SANTE PUBLIQUE (MSP). and INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE (IRD). Enquete Nationale sur la Planification Familiale, la Fecondite et la Sante de la Population au Maroc (ENPS) 1987: rapport preliminaire. Rev. [National Survey of Family Planning, Fertility and Health of the Population of Morocco 1987: preliminary report. Rev.] [FRE] [Rabbat, Morocco and Columbia, Maryland], MSP and IRD, Feb. 1988. 20 p.

335. MORRIS, L., LEWIS, G., POWELL, D.L., ANDERSON, J., WAY, A., CUSHING, J., and LAWLESS, G. Contraceptive Prevalence Surveys: a new source of family planning data. Population Reports, Series M, No. 5. Baltimore, Johns Hopkins University, Population Information Program, May-Jun. 1981. 40 p.

336. MORROW, C.P. and HART, W.R. Ovaries. In: Romney, S.L., Gray, M.J., Little, A.B., Merrill, J.A., Quilligan, E.J., and Stander, R.W., eds. Gynecology and obstetrics: the health care of women. 2nd ed. New York, McGraw-Hill, 1981. p. 1123-1181.

37. MOSHER, W.D. and BACHRACH, C.A. Contraceptive use. Vital and Health Statistics, Series 23, No. 12. Sept. 1986. 52 p.

338. MUNZ, R. Leben mit Kindern: Wunsch und Wirklichkeit. [Living sith children: desire and reality.] [GER] Vienna, Franz Deuticke Verlagsgesellschaft, 1985. 385 p.

339. MUSEY, V.C., COLLINS, D.C., MUSEY, P.I., MARTINO-SALTZMAN, D., and PREEDY, J.R.K. Long-term effect of a firt pregnancy on the secretion of prolactin. New England Journal of Medicine 316(5): 229-234. Jan. 29, 1987.

340. NDIAYE, S., SARR, I., and AYAD, M. Senegal: Enquete Demographique et de Sante au Senegal 1986. [Senegal Demographic and Health Survey 1986.] [FRE] Dakar, Senegal and Columbia, Maryland, Senegal Ministry of Economics and Finance and Institute for Resource Development/Westinghouse, Mar. 1988. 173 p.

341. NEUBERGER, J., FORMAN, D., DOLL, R., and WILLIAMS, R. Oral contraceptives and hepatocellular carcinoma. British medical Journal 292(6532): 1355-1357. May 24, 1986.

342. NEWHOUSE, M.L., PEARSON, R.M., FULLERTON, J.M., BOESEN, E.A.M., and SHANNON, H.S. A case control study of carcinoma of the ovary. British Journal of Preventive and Social Medicine 31(3): 148-153. Sept. 1977.

343. NILSSON, L. and SOLVELL, L. clinical studies on oral contraceptives--a randomized, doubleblind, crossover study of 4 different lreparations (Anovlar Mite, Lyndiol Mite, Ovulen, and Volidan). Acta Obstetricia et Gynecologica Scandinavica 46(Suppl. 8): 1-31. 1967.

344. NILSSON, S. Oral contraceptives during lactation: transfer of contraceptive steroids and estradiol to human milk. [Abstract] Doctoral dissertation, Uppsala University, 1978. 38 p.

345. NILSSON, S., MELLBIN, T., HOFVANDER, Y., SUNDELIN, C., VALENTIN, J., and NYGREN, K.G. Long-term follow-up of children breast-fed by mothers using oral contraceptives. Contraception 34(5): 443-457. Nov. 1986.

346. OLSSON, H., BORG, A., EWERS, S.-B., FERNO, M., MOLLER, T., and RANSTAM, J. A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer. Medical Oncology and Tumor Pharmacotherapy 3(2): 77-81. 1986.

347. OLSSON, H., MOLLER, T.R., RANSTAM, J., BORG, A., and FERNO, M. Early oral contraceptive use as a prognostic factor in breast cancer. Anticancer Research 8: 29-32. 1988.

348. OLSSON, H., OLSSON, M.L., MOLLER, T.R., RANSTAM, J., and HOLM, P. Oral contraceptive use and breast cancer in young women in Sweden. [Letter] Lancet 1(8431): 748-749. Mar. 30, 1985.

349. ONNIS, A., MARCHETTI, M., and GRAZIOTTIN, A. Hormones and risk of breast cancer. European Journal of Gynaecological Oncology 4(1): 13-17. 1983.

350. ORY, H. Functional ovarian cysts and oral contraceptives: negative association confirmed surgically. Journal of the American Medical Association 228(1): 68-69. Apr. 1, 1974.

351. ORY, H., COLE, P., MACMAHON, B., and HOOVER, R. Oral contraceptives and reduced risk of benign breast diseases. New England Journal of Medicine 294(8): 419-422. Feb. 19, 1976.

* 352. ORY, H.W. The noncontraceptive health benefits from oral contraceptive use. Family Planning Perspectives 14(4): 182-184. Jul.-Aug. 1982.

353. ORY, H.W., FORREST, J.D., and LINCOLN, R. Making choices: evaluating the health risks and benefits of birth control methods. New York, Alan Guttmacher Institute, 1983. 72 p.

354. ORY, H.W. and WOMEN'S HEALTH STUDY. Ectopic pregnancy and intrauterine contraceptive devices: new perspectives. Journal of the American Colle of Obstetricians and Gynecologists 57(2): 137-144. Feb. 1981.

355. OSSER, S., GULLBERG, B., LIEDHOLM, P., and SJOBERG, N.-O. Risk of pelvic inflammatory disease among intrauterine-device users irrespective of previous pregnancy. Lancet 1(8165): 386-388. Feb. 23, 1980.

356. PAFFENBARGER, R.S., Jr., FASAL, E., SIMMONS, M.E., and KAMPERT, J.B. Cancer risk as related to use of oral contraceptives during fertile years. Cancer 39(4, Suppl.): 1887-1891. Apr. 1977.

357. PAFFENBARGER, R.S., Jr., KAMPERT, J.B., and CHANG, H.G. Characteristics that predict risk of breast cancer before and after the menopause. American Journal of Epidemiology 112(2): 258-268. Aug. 1980.

358. PAIGE, K.E. Effects of oral contraceptives on affective fluctuations associated with the menstrual cycle. Psychosomatic Medicine 33(6): 515-537. Nov. 1971.

359. PASQUALE, S.A. Rationale for a triphasic oral contraceptive. Journal of Reproductive Medicine 29(Suppl. 7): 560-567. Jul. 1984.

360. PASQUALE, S.A. and YULIANO, E. Clinical results with a new low dose oral contraceptive utilizing norethindrone-ethinyl estradiol. Contraception 12(5): 495-503. Nov. 1975.

361. PAUL, C., SKEGG, D.C.G., SMEIJERS, J., and SPEARS, G.F.S. Contraceptive practice in New Zealand. New Zealand Medical Journal 101(859): 809-813. Dec. 14, 1988.

* 362. PAUL C., SKEGG, D.C.G., SPEARS, G.F.S., and KALDOR, J.M. Oral contraceptives and breast cancer: a national study. British Medical Journal 293(6549): 723-726. Sep. 20, 1986.

363. PAULSEN, M.L., VARADAY, A., BROWN, B.W., and KALMAN, S.M. A randomized contraceptive trial comparing a daily progestogen with a combined oral contraceptive steroid. Contraception 9(5): 497-506. May 1974.

364. PEARSON, O.H., LLERENA, O., LLERENA, L., MOLINA, A., and BUTLER, T. Prolactin-dependent rat mammary cancer: a model for man? Transactions of the Assn. of American Physicians 82:225-238. 1969.

365. PERALTA, O., DAZ, S., JUEZ, G., HERREROS, C., CASADO, M.E., SALVATIERRA, A.M., MIRANDA, P., DURN, E., and CROXATTO, H.B. Fertility regulation in nursing women: 5. Long-term influence of a low-dose combined oral contraceptive initiated at day 90 postpartum upon lactation and infant growth. Contraception 27(1): 27-38. Jan. 1983.

366. PERCIVAL-SMITH, R.K.L., MORRISON, B.J., SIZTO, R., and ABERCROMBIE, B. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women. Contraception 35(2): 179-187. Feb. 1987.

367. PERLMAN, J. Recent research on OC use and breast cancer risk. Presented at US Food and Drug Administration Fertility and Maternal Health Drugs Advisory Committee Meeting, Rockville, Maryland, Jan. 5, 1989.

368. PERU. NATIONAL INSTITUTE OF STATISTICS (NIS). and INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE (IRD). Ecuesta Demografica y de salud familiar (endes 1986): resultados preliminares. [Peru Demographic and Health Survey 1986: preliminary results.] [SPA] Lima, Peru and [Columbia, Maryland], NIS and IRD, Mar. 1987. 28 p.

* 369. PETITTI, D.B. and WINGERD, J. Use of oral contraceptives, cigarette smoking, and risk of subarachnoid haemorrhage. Lancet 2(8083): 234-236. Jul. 29, 1978.

* 370. PETITTI, D.B., WINGERD, J., PELLEGRIN, F., and RAMCHARAN, S. Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease. American Journal of Epidemiology 108(6): 480-485. Dec. 1978.

371. PIKE, M.C. Breast cancer and oral contraceptives. [Letter] Lancet 2(8465): 1180-1181. Nov. 23, 1985.

372. PIKE, M.C. Fertility and its effects on health. In: Diggory, P., Potts, M., and Teper, S., eds. natural human fertility: social and biological determinants. London, MacMillan Press, 1987. p. 161-189.

* 373. PIKE, M.C. and CHILVERS, C. Hormonal contraception and breast cancer. In: Wolff, J.-P. and Scott, J.S., eds. Hormones and sexual factors in human cancer aetiology. Amsterdam, Excerpta Medica, 1984. p. 83-99.

374. PIKE, M.C., HENDERSON, B.E., KRAILO, M.D., DUKE, A., and ROY, S. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 2(8356): 926-930. Oct. 22, 1983.

375. PINCUS, G., ROCK, J., GARCIA, C.-R., RICE-WRAY, E., PANIAGUA, M., and RODRIGUEZ, I. Fertility control with oral medication. American Journal of Obstetrics and Gynecology 75(6): 1333-1346. Jun. 1958.

376. PINCUS, G., ROCK, J., and GARCIA, C.R. Effects of certain 19-nor steroids upon reproductive processes. Annals of the New York Academy of Sciences 71: 677-690. Jul. 30, 1958.

377. PINOTTI, J.A., TEIXEIRA, L.C., PISANI, R.C.B., and BASTOS, S.R. Estrogen receptors in breast cancer--therapeutic response to the treatment of recurrences. International Journal of Gynaecology and Obstetrics 25(2): 127-131. Apr. 1987.

378. PIOTROW, P.T. and LEE, C.M. Oral contraceptives--50 million users. Population Reports, Series A, No. 1. Washington, D.C., Population Information Program, Apr. 1974. 28 p.

379. PIPER, J.M. Oral contraceptives and cervical cancer. Gynecologic Oncology 22(2): 1-14. Sep. 1985.

380. PLUMMER, F.A., SIMONSEN, J.N., CAMERON, D.W., NDINYA-ACHOLA, J.O., GAKINYA, M., KARASIRA, P., PIOT, P., RONALD, A.R., KIMATA, J., D'COSTA, L.J., and NGUGI, E.N. Genital ulcers and oral contraceptives facilitate male-female transmission of HIV. May 1987. 17 p. (Unpublished)

381. PORTER, J.B., HUNTER, J.R., DANIELSON, D.A., JICK, H., and STERGACHIS, A. Oral contraceptives and nonfatal vascular disease--recent experience. Obstetrics and Gynecology 59(3): 299-302. Mar. 1982.

* 382. PORTER, J.B., HUNTER, J.R., JICK, H., and STERGACHIS, A. Oral contraceptives and nonfatal vascular disease. Obstetrics and Gynecology 66(1): 1-4. Jul. 1985.

383. PORTER, J.B., JICK, H., and WALKER, A.M. Mortality among oral contraceptive users. Obstetrics and Gynecology 70(1): 29-32. Jul. 1987.

384. POTTS, M. Oral contraceptives and beast cancer. Presented at US Food and Drug Administration Fertility and Maternal Health Drugs Advisory Committee Meeting, Rockville, Maryland, Jan. 5, 1989.

385. POTTS, M., VLUGT, T. VAN DER, PIOTROW, P.T., GAIL, L.J., and HUBER, S.C. Advantages of orals outweigh disadvantages. Population Reports, Series A, No. 2. Washington, D.C., Population Information Program, Mar. 1975. 24 p.

* 386. PRENTICE, R.L. and THOMAS, D.B. On the epidemiology of oral contraceptives and disease. In: Klein, G. and Weinhouse, S., eds. Advances in cancer research. Orlando, Florida, Academic Press, 1987. (Vol. 49) p. 285-401.

387. PRESTON, S.N. A report of a collaborative dose-response clinical study using decreasing doses of combination oral contraceptives. Contraception 6(1): 17-35. Jul. 1972.

388. PRESTON, S.N. A report of the correlation between the pregnancy rates of low estrogen formulations and pill-taking habits of females studied. Journal of Reproductive Medicine 13(2): 75-77. Aug. 1974.

389. PRIMARY HEALTH CARE OPERATIONS RESEARCH (PRICOR). Household survey identifies patterns of use and payment for health care: Brazil; community financing of primary health care. PRICOR Interim Report No. 12, Sep. 1985. 2 p.

390. PRSIC, J. and KICOVIC, P.M. Preliminary experience with a new low-oestrogen content combined oral contraceptive. Current Medical Research and Opinion 2(4): 204-210. 1974.

391. QUINN, T.C., GLASSER, D., CANNON, R.O., MATUSZAK, D.L., DUNNING, R.W., KLINE, R.L., CAMPBELL, C.H., ISRAEL, E., FAUCI, A.S., and HOOK, E.W., 3rd. Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. New England Journal of Medicine 318(4): 197-203. Jan. 28, 1988.

* 392. RAMCHARAN, S., PELLEGRIN, F.A., RAY, R., and HSU, J.-P. The Salnut Creek Contraceptive Drug Study: a prospective study of the side effects of oral contraceptives. Vol 3. An interim report--a comparison of disease occurrence leading to hospitalization or death in users and nonusers of oral contraceptives. Bethesda, Maryland, US Department of Health and Human Services, National Institute of Child Health and Human Behavior, Jan. 1981. (Center for Population Research Monograph; NIH Publication No. 81-564) 349 p.

393. RANDLE, N. Antibiotic-and anticonvulsant-induced oral contraceptive failure. Journal of Pharmacy Technology 1(6): 246-249. Nov.-Dec. 1985.

* 394. RAVENHOLT, R.T., KESSEL, E., SPEIDEL, J.J., TALWAR, P.P., and LEVINSKI, M.J. A comparison of symptoms associated with the use of three oral contraceptives: a double blind crossover study of Ovral, Norinyl, and Norlestrin. [1977]. 31 p. (Unpublished)

395. RAVENHOLT, R.T. and PIOTROW, P.T. Use of oral contraceptives in developing countries. Pakistan Journal of Medical Research 8(3): 213-241. Jul. 1969.

396. RAVENHOLT, R.T., PIOTROW, P.T., and SPEIDEL, J.J. Use of oral contraceptives: a decade of controversy. International Journal of Gynaecology and Obstetrics 8(6, Pt. 2): 941-956. Nov. 1970.

397. RAVNIHAR, B., PRIMIC AKELJ, M., KOMELJ, K., and STARE, J. A case-control study of breast cancer in relation to oral contraceptive use in Slovenia. Neoplasma 35(1): 109-121. 1988.

398. REESE, M. and HATCHER, R.A. Instructions for minipill users. Contraceptive Technology Update 6(1): 21. Jan. 1985.

399. RICE-WRAY, E., SCHULTZ-CONTRERAS, M., GUERRERO, I., and ARANDA-ROSELL, A. Long-term administration of norethindrone in fertility control. Journal of the American Medical Association 180(5): 355-358. May 5, 1962.

400. RICHART, R.M., BECKER, T.M., FERENCZY, A.M., REID, R., and TOWNSEND, D.E. HPV DNA: quicker ways to discern viral types. Contemporary OB/GYN 33(4): 112-133. Apr. 1989.

401. RINEHART, W. Minipill--a limited alternative for certain women. Population Reports, Series A, No. 3. Washington, D.C., Population Information Program, Sep. 1975. 15 p.

402. RINEHART, W., KOLS, A., and MOORE, S.H. Healthier mothers and children through family planning. Population Reports, Series J, No. 27. Baltimore, Johns Hopkins University, Population Information Program, May-Jun. 1984. 40 p.

403. RIVERA, R., ALMONTE, H., ARREOLA, M., LOPEZ, F., MONARREZ, G., NAVARRO, C., ORTIZ, E., PERKIN, G.W., and RUIZ, R. The effects of three different regimens of oral contraceptives and three different intrauterine devices on the levels of hemoglobin, serum iron and iron binding capacity in anemic women. Contraception 27(3): 311-327. Mar. 1983.

404. ROBERTSON, E.M., ed. Identify and manage potentially serious OC/drug interactions. Contraceptive Technology Update 8(7): 90-92. Jul. 1987.

405. ROBERTSON, E.M., ed. OC use for one year or more cuts endometrial cancer risk. Contraceptive Technology Update 8(4): 47-48. Apr. 1987.

406. ROBERTSON, E.M., ed. OCs protect against ovarian cancer: effect may last as long as 15 years. Contraceptive Technology Update 8(4): 48-49. Apr. 1987.

407. ROBLES, R.R., MARTINEZ, R.E., VERA, M., and ALEGRIA, M. Sociocultural factors associated with contraceptive use in Puerto Rico. PAHO Bulletin 21(4): 395-404. 1987.

408. ROBLES R.R., MARTINEZ, R.E., VERA, M., and ALEGRIA, M. Sociocultural factors associated with contraceptive use in Puerto Rico. Bulletin of the Pan American Health Organization 21(4): 395-404. 1987.

409. ROCHAT, R.W., STRAUSS, L.T., SPECKHARD, M., and SENANAYAKE, P. Contraception during lactation--doctors' worldwide practice. IPPF Medical Bulletin 15(3): 4. Jun. 1981.

410. ROCK, J., PINCUS, G., and GARCIA, C.R. Effects of certain 19-nor steroids on the normal human menstrual cycle. Science 124(3227): 891-893. Nov. 1, 1956.

411. ROHAN, T.E. and MCMICHAEL, A.J. Oral contraceptive agents and breast cancer: a population-based case-control study. Medical Journal of Australia 149(10): 520-526. Nov. 21, 1988.

412. ROOKS, J.B., ORY, H.W., ISHAK, K.G., STRAUSS, L.T., GREENSPAN, J.R., HILL, A.P., and TYLER, C.W., Jr. Epidemiology of hepatocellular adenoma: the role of oral contraceptive use. [ENG, summary in FRE] In: Institut National de la Sante et de la Recherche Medicale (INSERM). Conseil Superieur de l'Information Sexuelle. A regulation of fertility: evaluation and perspectives. Paris, INSERM, 1979. p. 131-146.

* 413. ROSENBERG, L., KAUFMAN, D.W., HELMRICH, S.P., MILLER, D.R., STOLLEY, P.D., and SHAPIRO, S. Myocardial infarction and cigarette smoking in women younger than 50 years of age. Journal of the American Medical Association 253(20): 2965-2969. May 24-31, 1985.

414. ROSENBERG, L., MILLER, D.R., KAUFMAN, D.W., HELMRICH, S.P., STOLLEY, P.D., SCHOTTENFELD, D., and SHAPIRO, S. Breast cancer and oral contraceptive use. American Journal of Epidemiology 119(2): 167-176. Feb. 1984.

415. ROSENBERG, L., SHAPIRO, S., SLONE, D., KAUFMAN, D.W., HELMRICH, S.P., MIETTINEN, O.S., STOLLEY, P.D., ROSENSHEIN, N.B., SHOTTENFELD, D., and ENGLE, R.L., Jr. Epithelial ovarian cancer and combination oral contraceptives. Journal of the American Medical Association 247(23): 3210-3212. Jun. 18, 1982.

416. ROSERO-BIXBY, L. and OBERLE, M. Tabaquismo en la mujer Costarricense, 1984-85. [Tobacco use in Costa Rican women.] [SPA] Ciencias Sociales 35: 95-102. 1987.

417. ROY, M., MORIN, C., CASAS-CORDERO, M., and MEISELS, A. Human papillomavirus and cervical lesions. Clinical Obstetrics and Gynecology 26(4): 949-967. Dec. 1983.

418. ROYAL COLLEGE OF GENERAL PRACTITIONERS. Oral contraceptives and health: an interim report from the Oral Contraception Study of the Royal College of General Practitioners. New York, Pitman, 1974. 100 p.

419. ROYAL COLLEGE OF GENERAL PRACTITIONERS. RECORDS UNIT AND RESEARCH ADVISORY SERVICE. Oral contraception and thrombo-embolic disease. Journal of the Royal College of General Practitioners 13: 267-279. 1967.

420. ROYAL COLLEGE OF GENERAL PRACTITIONERS' ORAL CONTRACEPTION STUDY. Effect on hypertension and benign breast disease of progestagen component in combined oral contraceptives. Lancet 1(8012): 624. Mar. 19, 1977.

421. ROYAL COLLEGE OF GENERAL PRACTITIONERS' ORAL CONTRACEPTION STUDY. Oral contraceptives, venous thrombosis, and varicose veins. Journal of the Royal College of General Practitioners 28(192): 393-399. Jul. 1978.

422. ROYSTON, E. and LOPEZ, A.D. On the assessment of maternal mortality. World Health Statistics Quarterly 40: 214-224. 1987.

423. RUDEL, H.W., MAQUEO, M., CALDERONE, J., and MARTINEZ-MANATOU, J. Safety and effectiveness of a new low-dose kral contraceptive: a three-year study of 1,000 women. Journal of Reproductive Medicine 21(2): 79-88. Aug. 1978.

424. RUSSELL, M. and RAMCHARAN, S. Oral contraceptive estrogen content and adverse effects: has a dose-response relationship been established? Canadian Family Physician 33: 445-460. Feb. 1987.

425. RYDER, N.B. and WESTOFF, C.F. Use of oral contraception in the United States, 1965. Science 153(3741): 1199-1205. Sep. 9, 1966.

426. SABRA, A. and BONNAR, J. Hemostatic system changes induced by 50 [mu]g and 30 [mu]g estrogen/progestogen oral contraceptives: modification of estrogen effects by levonorgestrel. Journal of Reproductive Medicine 28(Suppl. 1): 85-91. Jan. 1983.

427. SARTORETOO, J.N., ORTEGA-RECIO, J.C., MORAES, R., and NAVAS FILHO, F. Clinical studies with a low dose estrogen-progestogen combination. Contraception 15(5): 563-570. May 1977.

428. SARTWELL, P.E., MASI, A.T., ARTHES, F.G., GREENE, G.R., and SMITH, H.E. Thromboembolism and oral contraceptives: an epidemiologic case-control study. American Journal of Epidemiology 90(5): 365-380. Nov. 1969.

429. SAYED, H.A.A.H., EL-KHORAZATY, M.N., and WAY, A.A. Fertility and family planning in Egypt: 1984. Cairo, Egypt and Columbia, Maryland, National Population Council and Westinghouse Public Applied Systems, Dec. 1985. 313 p.

430. SCHATZKIN, A., GREENWALD, P., BYAR, D.P., and CLIFFORD, C.K. The dietary fat--breast cancer hypothesis is alive. Journal of the American Medical Association 261(22): 3284-3287. Jun. 9, 1989.

431. SCHELLEN, A.M.C.M. Preliminary experience with a sub-50 combined oral contraceptive, containing 35 micrograms ethinyl oestradiol and 1 mg norethisterone (NeoCon). Pharmatherapeutica 2(6): 412-415. 1980.

432. SCHIRM, A.L., TRUSSELL, J., MENKEN, J., and GRADY, W.R. Contraceptive failure in the United States: the impact of social, economic and demographic factors. Family Planning Perspectives 14(2): 68-75. Mar.-Apr. 1982.

433. SCHLESSELMAN, J.J. Cancer of the breast and reproductive tract in relation to use of oral contraceptives--a review of human studies. [Draft] Oct. 28, 1988. 44 p.

* 434. SCHLESSELMAN, J.J. Oral contraceptives in relation to cancer of the breast and reproductive tract: an epidemiological review. Presented at the 16th Current Fertility Control Symposium, London, Oct. 12-13, 1988. 25 p. (To be published by British Journal of Family Planning)

* 435. SCHLESSELMAN, J.J., STADEL, B.V., MURRAY, P., and LAI, S.-H. Breast cancer risk in relation to type of estrogen contained in oral contraceptives. Contraception 36(6): 595-613. Dec. 1987.

436. SCHWARTZ, R.W. Common gynecologic problems. In: Berkow, R., ed. The Merck manual. 14th ed. Vol. 2. Rahway, New Jersey, Merck Sharp and Dohme Research Laboratories, 1982. p. 17-25.

437. SEDLACEK, T.V., CUNNANE, M., and CARPINIELLO, V. Colposcopy in the diagnosis of penile condyloma. American Journal of Obstetrics and Gynecology 154(3): 494-496. Mar. 1986.

438. SENANAYAKE, P. (International Planned Parenthood Federation) [IPPF policies on oral contraceptives and AIDS] Personal communication, Mar. 7, 1989.

* 439. SHAPIRO, S., SLONE, D., ROSENBERG, L., and KAUFMAN, D.W. Oral-contraceptive use in relation to myocardial infarction. Lancet 1(8119): 743-747. Apr. 7, 1979.

440. SHELTON, J. (US Agency for International Development) [OC doses in Bangladesh] Personal communication, Feb. 10, 1989.

441. SHELTON, J.D. and HARRIS, J. (US Agency for International Development) [Genital ulcers, OCs, and HIV infection] Personal communication to F.A. Plummer, Jun. 10, 1987.

442. SHENFIELD, G.M. The clinical pharmacology of the oral contraceptive and drugs which alter its activity. Healthright 6(2): 27-30. Feb. 1987.

443. SHENFIELD, G.M. Drug interactions with oral contraceptive preparations. Medical Journal of Australia 144(4): 205-211. Feb. 17, 1986.

444. SIEDLECKY, S. Current usage of and attitudes towards contraception in Australia. Healthright 6(1): 7-16. Nov. 1986.

445. SILBERGELD, S., BRAST, N., and NOBLE, E.P. The menstrual cycle: a double-blind study of symptoms, mood and behavior, and biochemical variables. Psychosomatic Medicine 33(5): 411-428. Sep.-Oct. 1971.

446. SIMPSON-HEBERT, M. and HUFFMAN, S.L. The contraceptive effect of breastfeeding. Studies in Family Planning 12(4): 125-133. Apr. 1981.

* 447. SKEGG, D.C.G. Potential for bias in case-control studies of oral contraceptives and breast cancer. American Journal of Epidemiology 127(2): 205-212. Feb. 1988.

448. SKEGG, D.C.G. (University of Otago) [Breast cancer and oral contraceptives] Personal communication, Feb. 3, 1989.

* 449. SLONE, D., SHAPIRO, S., KAUFMAN, D.W., ROSENBERG, L., MIETTINEN, O.S., and STOLLEY, P.D. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. New England Journal of Medicine 305(8): 420-424. Aug. 20, 1981.

450. SNOWBALL, S. and TAYLOR, W. Effects of short-term treatment with a combined oestrogen-progestin oral contraceptive on biliary lipids and cholesterol saturation index in young women. Journal of Steroid Biochemistry 22(2): 257-261. Feb. 1985.

451. SPAIN. NATIONAL INSTITUTE OF STATISTICS (NIS). Encuesta de fecundidad 1985: avance de resultados. [Fertility survey 1985: advance results.] [SPA] [Madrid], Spain, NIS, 1986. 237 p.

452. SPEIDEL, J.J., RAVENHOLT, R.T., and IRVINE, M.E. Liberalized policies for distribution of oral contraceptives. Studies in Family Planning 5(2): 62-67. Feb. 1974.

453. SPEROFF, L. Oral contraception: monophasics vs. multiphasics--is there a difference? 1988. 27 p. (Unpublished)

454. SPEROFF, L., ARCHER, D.F., and MISHELL, D.R. Multiphasic and monophasic OCs: is there a difference? [Symposium dialogue] Contemporary Ob/Gyn (Special Issue): 124-126, 129-130, 133-135, 138, 140, 142, 145. 1988.

455. SPRING, S.B. and GRUBER, J. Relationship of DNA viruses and cervical carcinoma. Journal of the National Cancer Institute 75(3): 589-590. Sep. 1985.

456. SRI LANKA. MINISTRY OF PLAN IMPLEMENTATION. DEPARTMENT OF CENSUS AND STATISTICS (DCS). and INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE (IRD/W). Sri Lanka Demographic and Health Survey 1987. [Colombol, Sri Lanka. and [Columbia, Maryland], DCS and IRD/W, Jul. 1987. 22 p.

* 457. STADEL, B.V. Oral contraceptives and cardiovascular disease: Pt. 1. New England Journal of Medicine: 305(11): 612-618. Sep. 10, 1981.

* 458. STADEL, B.V. Oral contraceptives and cardiovascular disease: Pt. 2. New England Journal of Medicine: 305(12): 672-677. Sep. 17, 1981.

* 459. STADEL, B.V., LAI, S., SCHLESSELMAN, J.J., and MURRAY, P. Oral contraceptives and premenopausal breast cancer in nulliparous women. Contraception 38(3): 287-299. Sep. 1988.

460. STADEL, B.V., RUBIN, G.L., WEBSTER, L.A., SCHLESSELMAN, J.J., and WINGO, P. Oral contraceptives and breast cancer in young women. Lancet 2(8461): 970-973. Nov. 2, 1985.

461. STADEL, B.V., RUBIN, G.L., WINGO, P.A., and SCHLESSELMAN, J.J. Oral contraceptives and breast cancer in young women. [Letter] Lancet 1(8478): 436. Feb. 22, 1986.

462. STADEL, B.V. and SCHLESSELMAN, J.J. Oral contraceptive use and the risk of breast cancer in women with a "prior" history of benign breast disease. American Journal of Epidemiology 123(3): 373-382. Mar. 1986.

463. STADEL, B.V., SCHLESSELMAN, J.J., and MURRAY, P.A. Oral contraceptives and breast cancer. [Letter] Lancet 1(8649): 1257-1258. Jun. 3, 1989.

* 464. STAMPFER, M.J., WILLETT, W.C., COLDITZ, G.A., SPEIZER, F.E., and HENNEKENS, C.H. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. New England Journal of Medicine 319(20): 1313-1317. Nov. 17, 1988.

465. STANLEY, K., STJERNSWARD, J. and KOROLTCHOUK, V. Women and cancer. World Health Statistics Quarterly 40(3): 267-278. 1987.

466. STEIGBIGEL, N.H., MAUDE, D.W., FEINER, C.J., HARRIS, C.A., SALTZMAN, B.R., KLEIN, R.S., et al. Heterosexual transmission of HIV infection. [Abstract] Presented at the 4th International Conference on AIDS, Stockholm, Sweden, Jun. 12-16, 1988.

467. STERN, E., FORSYTHE, A.B., and COFFELT, D.F. Steroid contraceptive use and cervical dysplasia: increased risk of progression. Science 196(4297): 1460-1462. Jun. 24, 1977.

468. STOLL, B.A. The basis of endocrine therapy. In: Endocrine therapy in malignant disease. London, W.B. Saunders, 1972. p. 111-137.

469. STOLLEY, P.D., TONASCIA, J.A., TOCKMAN, M.S., SARTWELL, P.E., RUTLEDGE, A.H., and JACOBS, M.P. Thrombosis with lowestrogen oral contraceptives. American Journal of Epidemiology 102(3): 197-208. Sep. 1975.

470. STRAUSS, L.T., SPECKHARD, M., ROCHAT, R.W., and SENANAYAKE, P. Oral contraception during lactation: a global survey of physician practice. International Journal of Gynaecology and Obstetrics 19(3): 169-175. Jun. 1981.

471. STURTEVANT, F.M. Breast cancer and oral contraceptives: critique of the proposition that high potency progestogen products confer excess risk. Biomedicine and Pharmacotherapy 38(8): 371-379. 1984.

472. SWEDEN. NATIONAL CENTRAL BUREAU OF STATISTICS (NCBS). Kvinnor och barn: intervjuer med kvinnor om familj och arbete. [Women and children: interviews with women about family and work.][SWE] Stockholm, NCBS, 1982. 101 p.

473. SWEDEN. WORLD FERTILITY SURVEY. Fertility survey in Sweden, 1981: a summary of findings. Woorburg, Netherlands, International Statistical Institute, Apr. 1984. (WFS Summary of findings No. 43) 18 p.

474. SWYER, G.I.M. Potency of progestogens in oral contraceptives--further delay of menses data. Contraception 26(1): 23-27. Jul. 1982.

475. SZOKA, P.R. and EDGREN, P.A. Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertility and Sterility 49(5, Suppl.): 315-38S. May 1988.

476. TALWAR, P.P., DINGFELDER, J.R., and RAVENHOLT, R.T. Increased risk of breakthrough bleeding when one oral-contraceptive tablet is missed. [Leter] New England Journal of Medicine 296(21): 1236-1237. May 26, 1977.

477. TAYOB, Y. and GUILlEBAUD, J. "Missed pill" conception: fact or fiction? [Letter] British Medical Journal 291(6488): 136-137. Jul. 13, 1985.

478. THAILAND. NATIONAL INSTITUTE OF DEVELOPMENT ADMINISTRATION (NIDA). RESEARCH CENTER. and MINISTRY OF PUBLIC HEALTH (MPH). NATIONAL FAMILY PLANNING PROGRAM. and MAHIDOL UNIVERSITY. INSTITUTE FOR POPULATION AND SOCIAL RESEARCH (IPSR). Thailand: summary report. [ENG, THA] [Bangkok], NIDA, and MPH. and IPSR, Apr. 1985. (Third Contraceptive Prevalence Survey) 29 p.

479. THAPA, S. A decade of Nepal's family planning program: achievements and prospects. Studies in Family Planning 20(1): 38-52. Jan.-Feb. 1989.

480. THAPA, S. (Family Health International) [Oral contraceptive use-effectiveness, Sri Lanka] Personal communication, May 1989.

481. THIERY, M., VAN KETS, H., and DEMOL, R. Clinical trial of a new oral contraceptive with a low oestrogen dosage: Restovar. Journal of International Medical Research 3(4): 279-283. 1975.

482. THOMAS, D.B., WHITEHEAD, A., and ROSEMAN, D. Invasive cervical cancer and combines oral contraceptives: WHO collaborative study of neoplasia and steroid contraceptives. British Medical journal 290(6473): 961-965. Mar. 30, 1985.

* 483. TIKkANEN, M.J. and NIKKILA, E.A. Oral contraceptives and lipoprotein metabolism. Journal of Reproductive Medicine 31(9, Suppl.): 9. 898-905. Sep. 1986.

484. TOGO. UNIT OF DEMOGRAPHIC RESEARCH. UNIVERSITY OF BENIN (UOB). and DEMOGRAPHIC AND HEALTH SURVEYS (DHS). INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE. Enquete Demographique et de Sante au Togo 1988: rapport preliminaire. [Togo Demographic and Health Survey 1988: preliminaire. [Togo Demographic and Health Survey 1988: preliminary report.][FRE] Lome, Togo and Columbia, Maryland, UOB and DHS, Fe. 1989. 15 p.

485. TOTH, A. Alternative causes of pelvic inflammatory disease. Journal of Reproductive Medicine 28(10, Suppl.): 699-702. Oct. 1983.

486. TREIMAN, K. and LISKIN, L. IUDs--a new look. Population Reports, Series B. No. 5. Baltimore, Johns Hopkins University, Populaiton Information Pjrogram, Mar. 1988. 32 p.

487. TRUSSELL, J. and KOST, K. Contraceptive failure in the United States: a critical review of the literature. Studies in Family Planning 18(5): 237-283. Sep.-Oct. 1987.

488. TUNISA. OFFICE NATIONAL DE LA MAFILLE ET DE LA POPULATION (NFP). and DEMOGRAPHIC AND HEALTH SURVEYS (DHS). INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE. Enquete demographique et de sante en Tunisie 1988: rapport preliminaire. [Tunisian Demographic and health Survey 1988: preliminary report.][FRE] Tunis, Tnisia and Columbia, Maryland, NFP and DHS, Dec. 1988. 23 p.

489. TUOMALA, R.E. Gunecologic infections. In: Kistner, R.W. Gynecology principles and practice. 4th ed. Chicago, Year Book Medical Publishers, 1986. p. 667-695.

490. TZONOU, A., DAY, N.E., TRICHOPOULOS, D., WALKER, A., SALIARAKI, N., PAPPOSTOLOU, M., and POLYCHRONOPOULOU, A. The epidemiology of ovarian cancer in Greece: a case-control study. european Journal of Cancer and Clinical Oncology 20(8): 1045-1052. Aug. 1984.

491. UGANDA. MINISTRY OF HEALTH (MOH). and DEMOGRAPHIC AND HEALTH SURVEYS (DHS). INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE. Uganda Demographic and Health Survey 1988-1989: preliminary report. [Kampapa], Uganda and [Columbia], Maryland, MOH and DHS, Mar. 1989. 18 p.

492. UNITED KINGDOM. OFFICE OF POPULAITON CENSUSES AND SURVEYS. Contraception, sterilisation and infertility. In: General Household Survey 1983. London, Her Majesty's Stationery Office, 1985. (Series GHS No. 13) p. 45-60.

493. UNITED NATIONS (UN). DEPARTMENT OF INTERNATIONAL ECONOMIC AND SOCIAL AFFAIRS. Levels and trends of contraceptive use as assessed in 1988. New York, UN, 1989. (Population Studies No. 110) 129 p.

494. UNITED STATES. AGENCY FOR INTERNATIONAL DEVELOPMENT. OFFICE OFFPOPULATION. Population: oral contraception and AIDS. [Telegram to AID worldwide] Jun. 1987. 1 p.

* 495. UTIAN, W.H. Oral contraceptive formulations--influence on user compliance and reliability of the method. Singapore Journal of Obstetrics and gynaecology 15(1, Suppl.): 6-13. Mar. 1984.

496. VAN DE GIESSEN, G.J. Onderzoek Genzinsvorming 1982: voorlopige uitkomsten. [netherlands Fertility Survey 1982: provisional results.][DUT, summary in ENG] Maadstatistiek van de Bevolking 31(4-5): 38-53. apr.-May 1983.

497. VAN DER VURST, J. Anticonceptie in Vlaanderen. [Contraception in Flanders.][DUT] [Dissertation: Utrecht, Rijksuniversiteit, 1985]. p. 249-324.

498. VANDENBROUCKE, J.P. Pregnancy-associated alpha-glyco-protein: the link between "the pill" and rheumatoid arthritis? [Letter] Lancet 1(8322): 1046. May 7, 1983.

499. VAUGHAN, B., TRUSSELL, J., MENKEN, J., and JONES, E.F. Contraceptive failure among married women in the United States, 1970-1973. Family Planning Perspectives 9(6): 251-258. Nov.-Dec. 1977.

500. VESSEY, M. (University of Oxford) [Breast cancer and oral contraceptives] Personal communication, Jan. 3, 1989.

* 501. VESSEY, M., BARON, J., DOLL, R., MCPHERSON, K., and YEATES, D. Oral contraceptives and breast cancer: final report of an epidemiological study. British Journal of Cancer 47(4): 455-462. Apr. 1983.

502. VESSEY, M., DOLL, R., PETO, R., JOHNSON, B., and WIGGINS, P. A long-term follow-up study of women using different methods of contraception--an interim report. Journal of Biosocial Science 8(4): 375-427. Oct. 1976.

503. VESSEY, M., METCALFE, A., WELLS, C., MCPHERSON, K., WESTHOFF, C., and YEATES, D. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. British Medical Journal 294(6586): 1518-1520. Jun. 13, 1987.

* 504. VESSEY, M.P. Cancer and the pill--some recent findings. Journal of Obstetrics and Gynaecology 4(Suppl. 1): S52-S56. Jan. 1984.

505. VESSEY, M.P. Female hormones and vascular disease--an epidemiological overview. British Journal of Family Planning 6(Suppl.): 1-12. Oct. 1980.

506. VESSEY, M.P. Oral contraceptives and breast cancer. IPPF Medical Bulletin 21(6): 1-2. Dec. 1987.

507. VESSEY, M.P. and DOLL, R. Investigation of relation between use of oral contraceptives and thromboembolic disease. British Medical Journal 2(5599): 199-205. Apr. 27, 1968.

508. VESSEY, M.P. and DILL, R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. British Medical Journal 2(5658): 651-657. Jun. 14, 1969.

509. VESSEY, M.P., LAWLESS, M., MCPHERSON, K., and YEATES, D. Neoplasia of the cervix uteri and contraception: a possible advrse effect of the pill. Lancet 2(8356): 930-934. Oct. 22, 1983.

* 510. VESSEY, M.P., LAWLESS, M., and YEATES, D. Oral contraceptives and stroke: findings in a large prospective study. British Medical Journal 289(6444): 530-531. Sjep. 1, 1984.

* 511. VESSEY, M.P., LAWLESS, M., YEATES, D., and MCPHERSON, K. Progestogen-only oral contraception: findings in a large prospective study with special reference to effectiveness. British Journal of Family Planning 10(4): 117-121. Jan. 1985.

512. VESSEY, M.P., MCPHERSON, K., YEATES, D., and DILL, R. Oral contraceptive use and abortion before first term pregnancy in relation to breast cancer risk. British journal of Cancer 45(2): 327-331. Feb. 1982.

513. VESSEY, M.P., VILLARD-MACKINTOSH, L., and YEATES, D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. contraception 35(5): 457-464. May 1987.

514. VIHKO, R.K. and APTERM, D.L. Steroids and the risk of breast cancer. Advances in Contraceptive Delivery Systems 2(2, 3): 198-207. Jun. 1986.

515. VIRTAVUO, T., PUNNONEN, R., KALLIO, H., MANNER, P., REHN, K., KANNEL, L., APAJALAHTI, E., AND HUSA, L. A multi-centre trial with a low-dosage combination type oral contraceptive. Pharmatherapeutica 1(8): 535-539. 1977.

516. VU, M.T. World population projections 1985: short- and long-term estimates by age and sex with related demographic statistics. Baltimore, Johns Hopkins University Press, 1985. 451 p.

517. WAHL, P., WALDEN, C., KNOPPE, R., HOOVER, J., WALLACE, R., HEISS, G., and RIFKIND, B. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. New England Journal of Medicine 309(15): 862-867. apr. 14, 1983.

518. WALDRON, T., ed. do oral contraceptives increase risk of contracting HIV? Contraceptive Technology Update 9(12): 145-148. Dec. 1988.

519. WANG, E., SHI, S., CEKAN, S.Z., LANDGREN, B.-M., and DICZFALUSY, E. Hormonal consequences of "missing the pill." Contraception 26(6): 545-565. Dec. 1982.

520. WARREN, C.W., OBERLE, M.W., MEDICAM, W., and MORRIS, L. Contraceptive use and fertility in Panama, 1984. International Family Planning Perspectives 13(2): 47-51. Jun. 1987.

521. WASHINGTON, A.E., GOVE, S., SCHACHTER, J., and SWEET, R.L. Oral contraceptives, Chlamydia trachomatis infection, and pelvic inflammatory disease: a word of caution about protection. Journal of the American medical Association 253(15): 2246-2250. Apr. 19, 1985.

522. WAY, A.A., CROSS, A.R., and KUMAR, S. Family planning in Botswana, Kenya and Zimbabwe. International Family Planning Perspectives 13(1): 7-11. Mar. 1987.

523. WEIR, R.J., BRIGGS, E., MACK, A., NAISMITH, L., TAYLOR, L., and WILSON, E. Blood pressure in women taking oral contraceptives. British Medical Journal 1(5907): 533-535. Mar. 23, 1974.

524. WEISS, N.S., LYON, J.L., LIFF, J.M., VOLLMER, W.M., and DALING, J.R. Incidence of ovarian cancer in relation to the use of oral contraceptives. International Journal of Cancer 28(6): 669-671. Dec. 15, 1981.

525. WEISS, N.S. and SAYVETZ, T.A. Incidence of endometrial cancer in relation to the use of oral contraceptives. NEW England Journal of Medicine 302(10): 551-554. Mar. 6, 1980.

526. WENTZ, A.C. Dysmenorrhea, premenstrual syndrome, and related disorders. In: Jones, H.W., 3rd, Wentz, A.C., and Burnett, L.S. Novak's Textbook of Gynecology. 11th ed. Baltimore, Williams & Silkins, 1988 p. 240-262.

527. WEST, C.P. The acceptability of a progestagen-only contraceptive during breat-feeding. Contraception 27(6): 563-569. Jun. 1983.

528. WILLETT, W.C., BAIN, C., HENNEKENS, C.H., ROSNER, B., and SPEIZER, F.E. Oral contraceptives and risk of ovarian cancer. Cancer 48(8): 1684-1687. Oct. 15, 1981.

529. WINGRAVE, S.J. Reduction in incidence in rheumatoid arthritis associated with oral contraceptives. Lancer 1(8064) 569-571. Mar. 18, 1978.

530. WINGRAVE, S.J. and KAY, C.R. Oral contraceptives and gall-bladder disease: Royal College of General Practitioners' Oral Contraception Study. Lancet 2(8305): 957-959. Oct. 30, 1982.

531. WINKELSTEIN, W., Jr. Smoking and cancer of the uterine cervix: hypothesis. american Journal of Epidemiology 106(4): 257-259. Oct. 1977.

532. WOLNER-HANSSEN, P. Akutt salpingitt og prevensjonsmidler. [Acute salpingitis and contraceptive use.][NOR] Tidsskrift for den Norske Laegeforening 106(24): 1924-1926. Aug. 30, 1986.

533. WOLNER-HANSEN, P., SVENSSON, L., MARDH, P.A., and WESTROM, L. Laparoscopic findings and contraceptive use in women sith signs and symptoms suggestive of acute salpingitis. Obstetrics and Gynecology 66(2): 233-237. Aug. 1985.

534. WOODS, K.L. Oral contraception and cancer of the female reproductive system. Journal of Clinical and Hospital Pharmacy 10(2): 123-135. Jun. 1985.

535. WORLD HEALTH ORGANIZATION (WHO). World health statistics annual: 1985. [ENG, FRE] Geneva, WHO, 1985. 531 p.

536. WORLD HEALTH ORGANIZATION (WHO). DIVISION OF FAMILY HEALTH. Maternal mortality rates, a tabulation of available information. 2nd ed. Geneva, WHO 1986. (FHE/86.3) 46 p.

537. WORLD HEALTH ORGANIZATION (WHO). DIVISION OF FAMILY HEALTH. The prevalence of nutritional anaemia in women in developing countries: a literature review. Geneva, WHO, 1979. (FHE/79.3) 118 p.

* 538. WORLD HEALTH ORGANIZATION (WHO). SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. and SPECIAL PROGRAMME ON AIDS. Report of a meeting on contraceptive methods and HIV infection. Geneva, WHO, Jun. 1987. 23 p. (Mimeo)

* 539. WORLD HEALT ORGANIZATION. Genital human papillomavirus infections and cancer: memorandum from a WHO meeting. Bulletin of the World health Organization 65(6): 817-827. 1987.

540. WORLD HEALTH ORGANIZATION. New strategies proposed for the study of breast cancer and the pill. Progress 8: 7-8, 1988.

* 541. WORLD HEALTH ORGANIZATION. SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. TASK FORCE ON ORAL CONTRACEPTIVES. A randomized, double-blind study of two combined two progestogen-only oral contraceptives. Contraception 25(3): 243-252. Mar. 1982.

542. WORLD HEALTH ORGANIZATION. SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. TASK FORCE ON SAFETY AND EFFICACY OF FERTILITY REGULATING METHODS. Report of meeting on breast cancer and oral contraceptives: Geneva, 27-28 Jun. 1988. 1988. 9 p. (Unpublished)

* 543. WORLD HEALTH ORGANIZATION. SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. TASK FORCE ON ORAL CONTRACEPTIVES. A randomized double-blind study of the effects of two low-dose combines oral contraceptives on biochemical aspects: report from a seven-centered study. Contraception 32(3): 223-236. Sep. 1985.

544. WORLD HEALTH ORGANIZATION. SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. TASK FORCE ON ORAL CONTRACEPTIVES. Effects of hormonal contraceptives on milk volume and infant growth. Contraception 30(6): 505-522. Dec. 1984.

* 545. WORLD HEALTH ORGANIZATION. SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. A randomized, double-blind study of six combined oral contaceptives. Contraception 25(3): 231-241. Mar. 1982.

546. WORLD HEALTH ORGANIZATION. SPECIAL PROGRAMME ON AIDS. and SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. Contraceptive methods and human immunodeficiency virus (HIV). [Joint statement] Weekly Epidemiological Record 62(33): 244. Aug. 14, 1987.

547. WORLD HEALTH ORGANIZATION. TASK FORCE ON ORAL CONTRACEPTIVES, SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT, AND RESEARCH TRAINING IN HUMAN REPRODUCTION. Effects of hormonal contraceptives on breast milk composition and infant growth. Studies in Family Planning 19(6): 361-369. Nov.-Dec. 1988.

* 548. WORLD HEALTH ORGANIZATION. and UNITED STATES NATIONAL ACADEMY OF SCIENCES. Summary and conclusions of the WHO/NAS Workshop and Meeting on Breast Feeding and Fertility Regulations: Current Knowledge and Programme Implications. [1982]. 24 p. (Unpublished).

549. WOUTERSZ, T.B. A new ultra-low-dose combination oral contraceptive. Journal of Reproductive Medicine 28(Suppl. 1): 81-84. Jan. 1983.

550. WOUTERSZ, T.B. Three and one-half years' experience with a lower-dose combination oral contraceptive. Journal of Reproductive Medicine 16(6): 338-334. Jun. 1976.

* 551. WYNN, V. Effect of progesterone and progestins on carbohydrate metabolism. In: Bardin C.W., Milgrom, E., and Mauvais-Jarvis, L., eds. Progesterone and progestins. New York, Raven Press, 1983. p. 395-410.

522. WYNN, V. and GODSLAND, I. Effects of oral contraceptives on carbohydrate metabolism. Journal of Reproductive Medicine 31(9, Suppl.): 892-897. Sep. 1986.

553. WYNN, V., GODSLAND, I., CROOK, D., and SIMPSON, R. Carbohydrate and lipid metabolism in users of fixed-dose, combined oral contraceptives containing levonorgestrel or desogestrel. [Text accompanying slide presentation] Oct. 1988. 22 p. (Unpublished).

554. WYNN, V., GODSLAND, I., SIMPSON, R., and CROOK, D. Carbohydrate and lipid metabolism in low-dose oral contraception. 1988. 24 o. (Unpublished)

555. WYNN, V. and NITHTHYANANTHAN, R. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. American Journal of Obstetrics and Gynecology 142(6, Pt. 2): 766-772. Mar. 15, 1982.

556. YUAN, J.-M., YU, M.C., ROSS, R.K., GAO, Y.-T., and HENDERSON, B.E. Risk factors for breast cancer in Chinese women in Shanghai. Cancer Research 48(7): 1949-1953. Apr. 1, 1988.

557. ZACHARIAS, S., AGUILERA, E., ASSENZO, J.R., and ZANARTU, J. Effects of hormonal and nonhormonal contraceptives on lactation and incidence of pregnancy. Contraception 33(3): 203-213. Mar. 1986.

558. ZADOR, G. and NILSSON, B. Climical experience with a low-oestrogen, low-progestogen combined oral contraceptive: evaluation of a Swedish multicentre study. Pharmatherrapeutica 1(7): 453-461. 1977.

559. ZARKOVIC, G. Alterations of cervical cytology and steroid contraceptive use. International Journal of Epidemiology 14(3): 369-376. Sep. 1985.

560. ZIMBABWE. DEPARTMENT OF CENSUS AND STATISTICS (ZDCS). and DEMOGRAPHIC AND HEALTH SURVEYS. INSTITUTE FOR RESOURCE DEVELOPMENT/WESTINGHOUSE (IRD/W). Zimbabwe Demographic and Health Survey 1988: preliminary report. [Hararel], Zimbabwe and [Columbia, Maryland, ZDCS and IRD/W, Mar. 1989. 22 p.

ADDENDA

561. HONDURAS. MINISTRY OF PUBLIC HEALTH (MOH). and ASSOCIATION FOR FAMILY PLANNING IN HONDURAS (ASHONPLAFA). and MANAGEMENT SCIENCES FOR HEALTH (MSH). and FAMILY HEALTH INTERNATIONAL (FHI). Epidemiology and Family Health Survey Honduras, 1987: final report. [Tegucigalpa], Honduras, MOH and [Tegucigalpa], Honduras, ASHONPLAFA, and [Boston], MSH, and [Research Triangle Park, North Carolina, FHI, May 1989. 305 p.

562. MAZUR, A. Media coverage and public opinion on scientific controversies. Journal of Communication 31(3): 106-115. Summer 1981.

563. MITRA AND ASSOCIATES (MA). Bangladesh Contraceptive Prevalence Survey--1985: key tables. Dhaka, MA, 1985. 24 p.

564. SCHLESSELMAN, J.J., STADEL, B.V., MURRAY, P., and LAI, S. Breast cancer in relation to early use of oral contraceptives: no evidence of a latent effect. Journal of the American Medical Association 259(12): 1828-1833. Mar. 25. 1988.

565. SPELLACY, W.N. KALRA, P.S., BUHI, W.C., and BIRK, S.A. Pituitary and ovarian responsiveness to a graded gonadotropin releasing factor stimulation test in women using a low-estrogen or a regular type of oral contraceptive. American Journal of Obstetrics and Gynecology 137(1): 109-115. May 1, 1980.

566. VESSEY, M.P., MCPHERSON, K., VILLARD-MACKINTOSH, L., and YEATES, D. Oral contraceptives and breast cancer: latest findings in a large cohort study. British Journal of Cancer 59(4): 613-617. Apr. 1989.

COPYRIGHT 1988 Department of Health
COPYRIGHT 2004 Gale Group

Return to Brevicon
Home Contact Resources Exchange Links ebay